



INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION
(ISHLT)

**LUNG TRANSPLANTATION
CORE COMPETENCY CURRICULUM**

(ISHLT LTx CCC)

**SECOND
EDITION**

June 2017

THE EDUCATIONAL WORKFORCE OF THE
ISHLT PULMONARY TRANSPLANTATION COUNCIL

L. LEARD, G. DELLEGREN, and D. DILLING

Acknowledgements to First Edition Authors:
T. ASTOR, G. BERRY, K. CHAN, D. MASON, D. LEVINE, C. WIGFIELD

CONTACT:

EMAIL: LORRIANA.LEARD@UCSF.EDU

TEL: 708-327-2488
FAX: 708-327-2382



(V 2.0 June 15, 2017)

ISHLT PULMONARY TRANSPLANTATION COUNCIL EDUCATION WORKFORCE

CHAIR

LORRIANA LEARD, MD

UNIVERSITY OF CALIFORNIA SAN FRANCISCO MEDICAL CENTER
SAN FRANCISCO, CALIFORNIA, USA
LORRIANA.LEARD@UCSF.EDU

CO-CHAIRS

GORAN DELLEGREN, MD, PHD

SAHLGRENSKA UNIVERSITY HOSPITAL
GOTEBORG, SWEDEN
GORAN.DELLEGREN@VGREGION.SE

DANIEL DILLING, MD

LOYOLA UNIVERSITY MEDICAL CENTER
MAYWOOD, ILLINOIS, USA
DDILLIN@LUMC.EDU

ACKNOWLEDGEMENT OF PRIOR CURRICULUM CONTENT AUTHORS:

KEVIN M. CHAN, MD

UNIVERSITY OF MICHIGAN HEALTH SYSTEM
1500 EAST MEDICAL CENTER
3916 TAUBMAN CENTER, BOX 0360
ANN ARBOR, MI 48109
734-936-5047
734-936-7048 (FAX)
KEVICHAN@UMICH.EDU

DEBORAH J. LEVINE, MD

UT HEALTH CENTER @ SAN ANTONIO
7703 FLOYD CURL DR.
DEPT. OF SURGERY, MC 7841
SAN ANTONIO, TX 78229
210-567-5616
210-567-2877 (FAX)
LEVINEDJ@UTHSCSA.EDU

DAVID P. MASON, MD

CLEVELAND CLINIC FOUNDATION
THORACIC & CV SURGERY, J4-1
9500 EUCLID AVE.
CLEVELAND, OH 44195
216-444-4053
216-445-6876 (FAX)

MASOND2@CCF.ORG

GERRY J. BERRY MD

STANFORD UNIVERSITY MEDICAL CENTER
DEPT. ANATOMIC PATHOLOGY
300 PASTEUR DRIVE SUIT H 2110
STANFORD, CA 94305
650- 723- 7211
650-725-7409 (FAX)

GJBERRY@STANFORD.EDU

TODD L. ASTOR, MD

PULMONARY AND CRITICAL CARE UNIT
MASSACHUSETTS GENERAL HOSPITAL
55 FRUIT STREET, BULFINCH 148
BOSTON, MA 02114
617-623-9704

TASTOR@PARTNERS.ORG

ISHLT LTx CCC: LIST OF CONTENTS

I. INTRODUCTION TO TRANSPLANTATION: BACKGROUND AND ISHLT REGISTRY P 7

LEARNING OBJECTIVES

1. BACKGROUND
2. OUTCOMES IN LUNG TRANSPLANTATION
3. CHALLENGES IN LUNG TRANSPLANTATION
4. LUNG TRANSPLANTATION DATABASES AND ISHLT REGISTRY

SELECTED REFERENCES AND RESOURCES

II. EVALUATION AND MANAGEMENT OF THE LUNG TRANSPLANT CANDIDATE P 8

LEARNING OBJECTIVES

1. INDICATIONS FOR LUNG TRANSPLANT REFERRAL
2. TRANSPLANT CANDIDATE EVALUATION AND ONGOING MANAGEMENT
3. SPECIAL CONSIDERATIONS INCLUDING INFORMED CONSENT
4. SPECIAL CONSIDERATIONS: HIGH PANEL REACTIVE ANTIBODY SCREEN
5. URGENT INPATIENT EVALUATION
6. ECMO IN THE PRETRANSPLANT PATIENT

MINIMUM EXPERIENCE REQUIREMENT

SELECTED REFERENCES AND RESOURCES

III. LUNG ALLOGRAFT DONATION AND PROCUREMENT P 12

LEARNING OBJECTIVES

1. HISTORICAL NOTES AND BACKGROUND
2. DONOR EVALUATION AND MANAGEMENT
3. LUNG ALLOGRAFT PROCUREMENT
4. EX VIVO LUNG PERFUSION
5. ADDITIONAL LUNG ALLOGRAFT OPTIONS AND FUTURE DIRECTIONS

MINIMUM EXPERIENCE REQUIREMENT

SELECTED REFERENCES AND RESOURCES

IV. LUNG TRANSPLANTATION: SURGICAL AND POST-OPERATIVE MANAGEMENT P 16

LEARNING OBJECTIVES

1. IMMEDIATE POST TRANSPLANT MANAGEMENT
2. SURGICAL CONDUCT
3. POSTOPERATIVE COMPLICATIONS
4. SPECIAL CONSIDERATIONS

MINIMUM EXPERIENCE REQUIREMENT
SELECTED REFERENCES AND RESOURCES

V. REJECTION AFTER LUNG TRANSPLANTATION, IMMUNOSUPPRESSION PROTOCOLS AND COMPLICATIONS **P 18**

A. IMMUNOLOGIC CONCEPTS IN LUNG TRANSPLANTATION **P 18**

LEARNING OBJECTIVES

1. DEFINITIONS
2. NORMAL IMMUNE RESPONSE
3. IMMUNE RESPONSE TO ALLOGRAFT
4. TOLERANCE
5. IMMUNOGENETICS
6. NON-HLA ANTIGENS
7. CLINICAL APPLICATIONS OF TRANSPLANT IMMUNOLOGY AND TYPING
8. THE SENSITIZED RECIPIENT

MINIMUM EXPERIENCE REQUIREMENT

SELECTED REFERENCES AND RESOURCES

B. REJECTION IN THE LUNG TRANSPLANT RECIPIENT **P 19**

LEARNING OBJECTIVES

1. HYPERACUTE REJECTION
2. ACUTE CELLULAR REJECTION
3. ANTIBODY MEDIATED REJECTION
4. CHRONIC LUNG ALLOGRAFT DYSFUNCTION (OBSTRUCTIVE AND RESTRICTIVE)

C. IMMUNOSUPPRESSION REGIMENS POST LUNG TRANSPLANTATION **P 21**

LEARNING OBJECTIVES

1. INDUCTION
2. OVERVIEW OF IMMUNOSUPPRESSIVE AGENTS

MINIMUM EXPERIENCE REQUIREMENT

SELECTED REFERENCES AND RESOURCES

D. HEMATOLOGIC DISORDERS POST LUNG TRANSPLANTATION **P 23**

LEARNING OBJECTIVES

1. THROMBOCYTOPENIA
2. ANEMIA
3. LEUKOPENIA OR LEUKOCYTOSIS

MINIMUM EXPERIENCE REQUIREMENT

SELECTED REFERENCES AND RESOURCES

E. GASTROINTESTINAL ISSUES POST LUNG TRANSPLANTATION **P 24**

LEARNING OBJECTIVES

1. FREQUENT PROBLEMS AND THEIR POSSIBLE ETIOLOGIES
2. COLONIC ISSUES
3. SMALL BOWEL OBSTRUCTION
4. UPPER GASTROINTESTINAL ISSUES
5. GERD AND BOS

6. GI BLEED
7. BILIARY DISEASE
8. PANCREATITIS
9. GI COMPLICATIONS OF CYSTIC FIBROSIS PATIENTS
10. HEPATIC TOXICITY SECONDARY TO MEDICATION
11. HYPERAMMONNEMIA

MINIMUM EXPERIENCE REQUIREMENT

SELECTED REFERENCES AND RESOURCES

VI. LUNG TRANSPLANTATION PATHOLOGY

P 26

LEARNING OBJECTIVES

1. PATHOLOGY OF COMMON INDICATIONS FOR THORACIC TRANSPLANTATION
2. SPECIMEN ADEQUACY AND HANDLING
3. POST-OPERATIVE AND IMMEDIATE POST-TRANSPLANT GRAFT DYSFUNCTION (WITHIN 7 DAYS)
4. EARLY COMPLICATIONS FOLLOWING LUNG TRANSPLANTATION (1 WEEK – 6 MONTHS)
5. ACUTE CELLULAR REJECTION (ACR)
6. INFECTIONS IN LUNG ALLOGRAFT
7. ACUTE ANTIBODY MEDIATED/HUMORAL REJECTION (AMR)
8. AIRWAY INFLAMMATION/LYMPHOCYTIC BRONCHITIS/BRONCHIOLITIS
9. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)
10. LATE COMPLICATIONS (BEYOND 6 MONTHS)
11. CHRONIC AIRWAY REJECTION
12. CHRONIC VASCULAR REJECTION (CVR)
13. RECURRENCE OF NATIVE/PRIMARY LUNG DISEASE

SELECTED REFERENCES AND RESOURCES

VII. DIAGNOSIS AND MANAGEMENT OF INFECTIONS FOLLOWING LUNG TRANSPLANTATION

P 29

LEARNING OBJECTIVES

1. IMMUNE RESPONSE TO INFECTION
2. EVALUATION OF INFECTION IN THE PRE-TRANSPLANT CANDIDATE
3. SIGNIFICANCE OF INFECTIONS IN THE DONOR
4. IMPAIRED PHYSIOLOGIC MECHANISMS IN THE ALLOGRAFT AND IMPACT ON INFECTION
5. OVERVIEW AND TIMELINE OF INFECTIONS AFTER LUNG TRANSPLANTATION
6. BACTERIAL INFECTIONS
7. ATYPICAL MYCOBACTERIAL INFECTIONS AND NOCARDIA
8. FUNGAL INFECTIONS
9. VIRAL INFECTIONS
10. NON-INFECTIOUS ALLOGRAFT SEQUELAE OF INFECTIOUS PATHOGENS
11. IMMUNE MONITORING AND INFECTION

SELECTED REFERENCES AND RESOURCES

IV. MALIGNANCIES FOLLOWING LUNG TRANSPLANTATION

LEARNING OBJECTIVES

1. INCIDENCE OF MALIGNANCY IN LUNG TRANSPLANT RECIPIENTS
2. PTLD
3. SKIN CANCER
4. LUNG CANCER
5. OTHER MALIGNANCIES

6. CANCER SCREENING IN LUNG TRANSPLANT CANDIDATES
7. MODULATION OF IMMUNOSUPPRESSION

SELECTED REFERENCES AND RESOURCES

V. MANAGEMENT OF METABOLIC COMPLICATIONS FOLLOWING LUNG TRANSPLANTATION

LEARNING OBJECTIVES

1. DIABETES
2. HYPERTENSION
3. OSTEOPOROSIS
4. METABOLIC SYNDROME

SELECTED REFERENCES AND RESOURCES

VI. REPRODUCTIVE HEALTH AFTER LUNG TRANSPLANTATION

LEARNING OBJECTIVES

1. REPRODUCTIVE IMPLICATIONS
2. CONTRACEPTION
3. PREGNANCY

SELECTED REFERENCES AND RESOURCES

ADDENDUM

P 34

INTRODUCTION

The purpose of this compendium is to provide a curriculum of core competencies in lung transplantation. The ISHLT Academy provides a concise synopsis of clinical *knowledge* and associated essential professional *skills* to facilitate the mastery of all surgical and medical aspects involved in the care of patients receiving lung transplantation.

This updated version or second edition of this compendium does not replace a textbook, but intends to provide an outline of essential topics and aims to assist with detailed review. This should be of benefit for both seasoned clinicians and current trainees. The former may find selective revision of complimentary areas in lung transplantation useful, whereas the latter may benefit from a more complete review of all topics during fellowship or other subspecialty training in lung transplantation.

Inevitably, some overlap of clinically related aspects may have occurred. Extensive referencing should assist selective review of published evidence for each topic.

This document also includes active hyperlinks and related multi-media resources. These should be considered during individual study to develop competency in various aspects of lung transplantation.

The core curriculum should also serve programs providing lung transplantation with a tool to review their standards of care, develop protocols and implement guidelines established in lung transplantation.

Wherever possible, specific *learning objectives* have been defined. Minimal recommended *clinical experience* has been proposed with the awareness that this may be variable dependent on individual professional background and regional program limitations. The outlines will also serve as a template for a post-graduate course curriculum to be provided by the ISHLT academy at future annual meetings.

The educational workforce of the Pulmonary Council of ISHLT hopes that this compendium will prove to be useful. We would welcome constructive feedback to further develop its scope and accuracy.

On behalf of the Pulmonary Council of ISHLT,

Lorriana Leard, MD
Chair of Second Edition
Nice, France 2018

Chris Wigfield MD FRCS
Chair of First Edition
Chicago, IL 2011

I. INTRODUCTION TO LUNG TRANSPLANTATION: BACKGROUND AND ISHLT REGISTRY

Learning Objectives for the Introduction to Lung Transplantation: Background and ISHLT Registry:

- 1) To establish context and historic background for lung transplantation.
- 2) To know indications and expected outcomes in lung transplantation.
- 3) To appreciate current challenges and limitations associated.
- 4) To utilize the ISHLT registry report and resources.

1. **Background**

- a. Historical Context
- b. First Lung Transplants
- c. Advent of Immunosuppression

2. **Outcomes in Lung Transplantation**

- a. Current expected survival rates
- b. Comparative survival
- c. Conditional survival after 1 year
- d. Outcomes dependent on native pulmonary disease process

3. **Challenges in Lung Transplantation**

- a. Donor Scarcity
- b. Waiting List mortality
- c. Chronic Lung Allograft Dysfunction

4. **Lung Transplantation Databases and ISHLT Registry**

- a. Data Access
- b. Statistics available
- c. Data submission

Selected Hyperlinks for the Introduction to Lung Transplantation: Background and ISHLT Registry:

- ISHLT Academy website: <http://www.ishlt.org/meetings/ishltAcademy.asp>
- Overall Lung and Adult Lung Transplantation Statistics:
<http://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry>
- *The Journal For Heart & Lung Transplantation* Website: www.jhltonline.org
- Scientific Registry of the International Society for Heart and Lung Transplantation: Introduction to the 2005 Annual Reports: <https://www.srtr.org/reports-tools/srtroptn-annual-data-report>
- The Unified Transplant Network established by the United States Congress under the National Organ Transplant Act (NOTA) of 1984: <http://www.optn.org>
- Eurotransplant Website: www.eurotransplant.nl
- ONT-WHO Global Observatory on Donation and Transplantation (global database on donation and transplantation):
<http://www.transplant-observatory.org/>

Selected References for the Introduction to Lung Transplantation: Background and ISHLT Registry:

- ISHLT Monograph Volume 4: History of International Heart and Lung Transplantation. Published: March 2010 Editors: James K. Kirklind, MD, Mandeep Mehra, MD, and Lori J. West, MD, PhD
- Mendeloff EN. The history of pediatric heart and lung transplantation. *Pediatr Transplant*. 2002 Aug;6(4):270-9.

II. EVALUATION AND MANAGEMENT OF THE LUNG TRANSPLANT CANDIDATE

Learning Objectives for the Evaluation and Management of the Lung Transplant Candidate:

- 5) Understand general and disease specific considerations for lung transplant referral
- 6) Review appropriate and cost effective testing, cancer screening, vaccination, consultation and multidisciplinary support of the lung transplant candidate
- 7) Understand the importance of —waitlist management for the transplant candidate
- 8) Understand the importance of informed consent for transplantation, high risk donor acceptance and research participation
- 9) Discuss and review risks associated with anti-HLA antibodies, elevated panel reactive antibody screens and desensitization therapies
- 10) Understand lung donor allocation schemes and the relationship to the urgent inpatient lung transplant evaluation

1. Indications for Lung Transplant Referral

- a. General considerations
 - i. End stage lung disease
 - ii. Ambulatory
 - iii. Maximal medical management
 - iv. Minimal or no co-morbid illness
 - v. Tobacco cessation
 - vi. Strong psychosocial support
 - vii. Physiologic age considerations
 - viii. Previous or current malignancy
 - ix. Systemic disease
 - x. Body Mass Index (BMI) considerations
 - xi. Colonization with highly resistant organisms (e.g. *Burkholderia cepacia* genomovar III, *M chelonae abscessus*)
 - xii. Mechanical ventilation
 - xiii. ECMO
- b. Disease specific listing considerations (including single or double LTx listing)
 - i. IPAH
 - ii. Emphysema
 - iii. CF
 - iv. IPF
 - v. Connective Tissue Disease
 - vi. Other

2. Transplant Candidate Evaluation and Ongoing Management

- a. Respiriologist / Pulmonologist
- b. Thoracic Surgeon
- c. Social Worker
- d. Psychiatrist/Psychologist
- e. Pre Transplant coordinator
- f. Financial coordinator
- g. Pharmacist
- h. Nutritionist
- i. Pre transplant education / Patient Support groups
- j. Pulmonary Rehabilitation
- k. Testing
 - i. Pulmonary
 1. Pulmonary function tests including ABG

2. 6MW/Shuttle test
3. Cardiopulmonary exercise test (CPET)
- ii. Radiographic
 1. High Resolution CT of the chest (HRCT)
 2. Perfusion (V/Q) scan
 3. Esophagram
 4. Bone densitometry
- iii. Cardiac
 1. EKG
 2. Echocardiogram
 3. Cardiac stress test
 4. Cardiac catheterization
 - a. Right
 - b. Left
- iv. Gastrointestinal
 1. EGD (?PEG tube placement)
 2. Colonoscopy
 3. 24 hour pH probe and manometry
- v. Renal
 1. 24 hour Creatinine Clearance
 2. Abdominal Ultrasound
- vi. Health Care Screening
 1. Dental examination
 2. Colon - Stool guaiac or FIT test, Colonoscopy
 3. Skin – Full body skin exam
 4. Prostate – PSA
 5. Breast - Mammogram
 6. Cervical/Ovarian – PAP Smear, HPV testing
- vii. Laboratories and serology
 1. Basic labs: Comprehensive panel, CBC, 24 hour creatinine clearance
 2. Infectious Serology: EBV, CMV, HIV, Toxoplasma, RPR, Hepatitis A, B, C
 3. Blood typing x 2 and HLA
 4. HLA testing: PRA and possibly single antigen testing
 5. Others to consider: Quantiferon TB Gold testing, Urine Toxicology, Nicotine or Cotinine
- viii. Vaccines
 1. Hepatitis B
 2. Pneumococcal
 3. Influenza
 4. Tetanus and Pertussis
- ix. Additional referrals as necessary
 1. Cardiology
 2. Gastroenterology
 - a. α 1-AT deficiency (hepatology)
 - b. CF (liver disease, DIOS etc.)

3. Special Considerations Including Informed Consent

- a. Hepatitis B or C
- b. HIV
- c. Acceptance of high risk donor
- d. Research participation

4. Special Considerations: High Panel Reactive Antibody Screen

- a. Desensitization therapy

b. Prospective and retrospective crossmatching

5. Urgent Inpatient Evaluation

- a. Mechanical ventilation
- b. ECMO
- c. Deconditioning

6. Lung Allocation Systems

- a. United States: Lung Allocation Score
- b. Europe: Eurotransplant allocation
- c. UK: Lung allocation
- d. Australia: Lung Allocation
- e. Other Countries: Lung Allocation

Minimum Experience Requirement for Evaluation and Management of the Lung Transplant Candidate:

(Modified from UNOS Membership Criteria)

- Participate in the care of 15 or more lung transplant candidates for a minimum of 3 months from the time of referral to the time of listing and/or transplantation.
- Participate in the care of 3 or more lung transplant candidates with an elevated PRA of > 25% from the time of patient referral to the time of transplantation incorporating desensitization procedures.
- Participate in the care of 3 or more lung transplant candidates undergoing urgent in-hospital evaluation for lung transplantation.

Selected Hyperlinks for the Evaluation and Management of the Lung Transplant Candidate:

- **A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34(1): 1-15: [http://www.jhltonline.org/article/S1053-2498\(14\)01181-4/fulltext](http://www.jhltonline.org/article/S1053-2498(14)01181-4/fulltext)**

Selected References for Evaluation and Management of the Lung Transplant Candidate:

- Gottlieb J**, Smits J, Schramm R, Langer F, Buhl R, Witt C, Strueber M, Reichenspumer H. Lung Transplantation in Germany Since the Introduction of the Lung Allocation Score. *Dtsch Arztebl Int.* 2017 Mar 17;114(11):179-185. doi: 10.3238/arztebl.2017.0179.
- Verleden SE**, Martens A, Ordies S, Heigl T, Bellon H, Vandermeulen E, Van Herck A, Sacreas A, Verschakelen J, Coudyzer W, Van Raemdonck DE, Vos R, Weynand B, Verleden GM, Vanaudenaerde B, Neyrinck A. Radiological Analysis of Unused Donor Lungs: A Tool to Improve Donor Acceptance for Transplantation? *Am J Transplant.* 2017 Mar 1.
- Crawford TC**, Grimm JC, Magruder JT, Ha J, Sciortino CM, Kim BS, Bush EL, Conte JV, Higgins RS, Shah AS, Merlo CA. Lung Transplant Mortality Is Improving in Recipients With a Lung Allocation Score in the Upper Quartile. *Ann Thorac Surg.* 2017 May;103(5):1607-1613.
- Ganapathi AM**, Mulvihill MS, Englum BR, Speicher PJ, Gulack BC, Osho AA, Yerokun BA, Snyder LR, Davis D, Hartwig MG. Transplant size mismatch in restrictive lung disease. *Transpl Int.* 2017 Apr;30(4):378-387.
- Lancaster TS**, Miller JR, Epstein DJ, DuPont NC, Sweet SC, Eghtesady P. Improved waitlist and transplant outcomes for pediatric lung transplantation after implementation of the lung allocation score. *J Heart Lung Transplant.* 2017 May;36(5):520-528
- Liu Y**, Vela M, Rudakevych T, Wigfield C, Garrity E, Saunders MR. Patient factors associated with lung transplant referral and waitlist for patients with cystic fibrosis and pulmonary fibrosis. *J Heart Lung Transplant.* 2017 Mar;36(3):264-271.
- Iribarne A**, Meltzer DO, Chauhan D, Sonett JR, Gibbons RD, Vigneswaran W, Russo MJ. Distribution of donor lungs in the United States: a case for broader geographic sharing. *Clin Transplant.* 2016 Jun;30(6):688-93.
- Egan TM**, Edwards LB. Effect of the lung allocation score on lung transplantation in the United States. *J Heart Lung Transplant.* 2016 Apr;35(4):433-9. Tsuang WM, Chan KM, Skeans MA, Pyke J, Hertz MI, Israni AJ, Robbins-Callahan L, Visner G, Wang X, Wozniak TC, Valapour M. Broader Geographic Sharing of Pediatric Donor Lungs Improves Pediatric Access to Transplant. *Am J Transplant.* 2016 Mar;16(3):930-7.
- Braun AT**, Dassenbrook EC, Shah AS, Orens JB, Merlo CA. Impact of lung allocation score on survival in cystic fibrosis lung transplant recipients. *J Heart Lung Transplant.* 2015 Nov;34(11):1436-41.
- Maxwell BG**, Mooney JJ, Lee PH, Levitt JE, Chhatwani L, Nicolls MR, Zamora MR, Valentine V, Weill D, Dhillon GS. Increased resource use in lung transplant admissions in the lung allocation score era. *Am J Respir Crit Care Med.* 2015 Feb 1;191(3):302-8.
- Lehr CJ**, Zaas DW. Candidacy for lung transplant and lung allocation. *Thorac Surg Clin.* 2015;25(1):1-15. doi: 10.1016/j.thorsurg.2014.09.001. Review. Erratum in: *Thorac Surg Clin.* 2015 May;25(2):235.
- Weill D**, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, Snell GI, Verleden GM, Zamora MR, Glanville AR. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant.* 2015 Jan;34(1):1-15. doi: 10.1016/j.healun.2014.06.014. Epub 2014 Jun 26.
- Gottlieb J**, Greer M, Sommerwerck U, Deuse T, Witt C, Schramm R, Hagl C, Strueber M, Smits JM. Introduction of the lung allocation score in Germany. *Am J Transplant.* 2014 Jun;14(6):1318-27.

Klinzing S, Brandi G, Raptis DA, Wenger U, Weber D, Stehberger PA, Inci I, Béchir M. Influence on ICU course, outcome and costs for lung transplantation after implementation of the new Swiss transplantation law. *Transplant Res.* 2014 Apr 1;3(1):9.

Kneidinger N, Winter H, Sisic A, Preissler G, Neurohr C, Czerner S, Weig T, Dolch M, Uberfuhr P, Schramm R. Munich lung transplant group: waiting list during the first 9 months of the lung allocation score era. *Thorac Cardiovasc Surg.* 2014 Aug;62(5):422-6.

Snyder JJ, Salkowski N, Skeans M, Leighton T, Valapour M, Israni AK, Hertz MI, Kasiske BL. The equitable allocation of deceased donor lungs for transplant in children in the United States. *Am J Transplant.* 2014 Jan;14(1):178-83.

Kotloff RM. Risk stratification of lung transplant candidates: implications for organ allocation. *Ann Intern Med.* 2013 May 7;158(9):699-700.

Crotti S, Iotti GA, Lissoni A, Belliato M, Zanierato M, Chierichetti M, Di Meo G, Meloni F, Pappalettera M, Nosotti M, Santambrogio L, Viganò M, Braschi A, Gattinoni L. Organ allocation waiting time during extracorporeal bridge to lung transplant affects outcomes. *Chest.* 2013 Sep;144(3):1018-1025.

Thabut G, Christie JD, Mal H, Fournier M, Brugière O, Leseche G, Castier Y, Rizopoulos D. Survival benefit of lung transplant for cystic fibrosis since lung allocation score implementation. *Am J Respir Crit Care Med.* 2013 Jun 15;187(12):1335-40.

Wille KM, Harrington KF, deAndrade JA, Vishin S, Oster RA, Kaslow RA. Disparities in lung transplantation before and after introduction of the lung allocation score. *J Heart Lung Transplant.* 2013 Jul;32(7):684-92.

Thabut G, Munson J, Haynes K, Harhay MO, Christie JD, Halpern SD. Geographic disparities in access to lung transplantation before and after implementation of the lung allocation score. *Am J Transplant.* 2012 Nov;12(11):3085-93.

De Oliveira NC, Osaki S, Maloney J, Cornwell RD, Meyer KC. Lung transplant for interstitial lung disease: outcomes before and after implementation of the united network for organ sharing lung allocation scoring system. *Eur J Cardiothorac Surg.* 2012 Mar;41(3):680-5.

Hoopes CW, Kukreja J, Golden J, Davenport DL, Diaz-Guzman E, Zwischenberger JB. Extracorporeal membrane oxygenation as a bridge to pulmonary transplantation. *J Thorac Cardiovasc Surg.* 2013 Mar;145(3):862-7; discussion 867-8.

Toyoda Y, Bhama JK, Shigemura N, Zaldonis D, Pilewski J, Crespo M, Bermudez C. Efficacy of extracorporeal membrane oxygenation as a bridge to lung transplantation. *J Thorac Cardiovasc Surg.* 2013 Apr;145(4):1065-70; discussion 1070-1.

Smits JM, Nossent GD, de Vries E, Rahmel A, Meiser B, Strueber M, Gottlieb J. Evaluation of the lung allocation score in highly urgent and urgent lung transplant candidates in Eurotransplant. *J Heart Lung Transplant.* 2011 Jan;30(1):22-8. doi: 10.1016/j.healun.2010.08.006.

Yusen RD, Shearon TH, Qian Y, Kotloff R, Barr ML, Sweet S, Dyke DB, Murray S. Lung transplantation in the United States, 1999-2008. *Am J Transplant.* 2010 Apr;10(4 Pt 2):1047-68.

Liu V, Zamora MR, Dhillion GS, Weill D. Increasing lung allocation scores predict worsened survival among lung transplant recipients. *Am J Transplant.* 2010 Apr;10(4):915-20.

Sweet SC. Update on pediatric lung allocation in the United States. *Pediatr Transplant.* 2009 Nov;13(7):808-13.

Nunley DR, Bauldoff GS, Holloman CH, Pope-Harman A. The lung allocation score and survival in lung transplant candidates with chronic obstructive pulmonary disease. *Lung.* 2009 Nov-Dec;187(6):383-7.

Titman A, Rogers CA, Bonser RS, Banner NR, Sharples LD. Disease-specific survival benefit of lung transplantation in adults: a national cohort study. *Am J Transplant.* 2009 Jul;9(7):1640-9.

Russo MJ, Iribarne A, Hong KN, Davies RR, Xydas S, Takayama H, Ibrahimiyeh A, Gelijs AC, Bacchetta MD, D'Ovidio F, Arcasoy S, Sonett JR. High lung allocation score is associated with increased morbidity and mortality following transplantation. *Chest.* 2010 Mar;137(3):651-7.

Orens JB, Garrity ER Jr. General overview of lung transplantation and review of organ allocation. *Proc Am Thorac Soc.* 2009 Jan 15;6(1):13-9.

Cocchiara G, Lo Monte AI, Romano G, Romano M, Buscemi G. Informed Consent in High-Risk Renal Transplant Recipients. *Transplantation Proceedings.* 2009;41(5):1524-6.

Halpern SD, Shaked A, Hasz RD, Caplan AL. Informing Candidates for Solid-Organ Transplantation about Donor Risk Factors. *N Engl J Med.* 2008 June 26, 2008;358(26):2832-7.

III. LUNG ALLOGRAFT DONATION AND PROCUREMENT

Learning Objectives for Lung Allograft Donation and Procurement:

- 11) To develop a clinically relevant understanding of donor brain death, the basic pathophysiology and donor certification issues
- 12) To differentiate types of donors as relevant to lung transplantation
- 13) Knowledge of waiting list and donor availability concerns
- 14) Lung allograft matching criteria
- 15) Procurement: Procedure and understanding of possible adverse events
- 16) Recognize options for donor management and allograft optimization
- 17) To be aware of future directions in lung allograft procurement

1. **Historical Notes and Background**

- a. General considerations
 - i. Overview and historical Perspective
 - ii. Brain Death Definition and Criteria
 - iii. Definitions of Donors (DDND v DDCD)
 - iv. Donor Scarcity and Waiting List
 - v. Definition of Standard v Extended Criteria Donors in LTx (SCD v ECD)

2. **Donor Offer and Evaluation Process**

- a. Matching Criteria in Lung Transplantation
 - i. Serology confirmation
 - ii. Size matching
 - iii. Laterality Issues
 - iv. Organ Procurement Consent
 - v. Allocation Scores and recipient matching
- b. Evaluation Process
 - i. Procurement Offer
 - ii. Provisional Acceptance
 - iii. Logistics and Confirmed Acceptance
 - iv. Donor Net systems/ IT technology
 - v. Etiology of Donor Lung Injury:
 1. Neuroendocrine Dysregulation
 2. Permeability and Pulmonary Edema
 3. Airway, Pulmonary and Pleural Trauma
 4. Aspiration Pneumonitis
 5. Respiratory Infections
 6. Ventilation related Issues
 - vi. Modified Evaluation process:
 1. High Risk Donors
 2. Donor type related (DDND v DDCD)
 3. Pediatric Donor
- c. Donor Assessment
 - i. Donor Information and Evidence Review
 - ii. Verification of Brain Death Certification
 - iii. UNOS donor Criteria
 - iv. Bronchoscopy of Donor Lungs
 - v. Visualization of Donor Lungs
 - vi. Additional Investigations
 - vii. Dialogue with Recipient Surgeon's Team
 - viii. Multiorgan Procurement Communication
- d. Donor Management and Optimization
 - i. Options for Allograft improvement in situ
 - ii. Fluid Management and Re-evaluation

- iii. Extended Criteria Donors

3. **Lung Allograft Procurement**

- a. Lung Procurement
 - i. Preparations and Dissection (with/ without Cardiac procurement)
 - ii. Antegrade Pulmoplegia Principles
 - iii. En Bloc Excision of Allografts: Essentials and Pitfalls
 - iv. Backbench Assessment and Retrograde Pulmoplegia
 - v. Lung Separation
 - vi. Transport Requirements
- b. Planned Ischemia and Reperfusion Preparation
 - i. Allograft Ischemia Basics
 - ii. Preparation of Donor Lung for Anastomoses
 - iii. Re-warming, Re-perfusion and Re-ventilation

4. **Additional Lung Allograft Options and Future Directions**

- a. Additional Lung Allograft Sources
 - i. Living Related Lung Donation
 - ii. Split Lung Allografts
 - iii. DDCD Lung Allografts
- b. Future Directions
 - i. Ex Vivo Lung Perfusion
 - ii. Xenografts in Lung Transplantation

Minimum Experience Requirement for Lung Donation and Procurement:

For recommendations see UNOS Statements on Lung Transplant Surgeon Certification Process: UNOS appendix B; Attachment I—XIII 73 pp.

- Reasonable Minimum experience: “10 or more Lung Allograft Procurements as Primary Surgeon under supervision of qualified lung transplant surgeon”. Case must be documented with Donor UNOS (or equivalent ID Number).
- Nota Bene: Lung Allograft procurement is associated with numerous pitfalls. To prevent adverse outcomes every effort to optimize a procurement surgeons’ skills and judgment is required. This can not be simply quantified in case numbers performed and is best developed in a dedicated thoracic transplant service.

Selected Hyperlinks for Lung Donation and Procurement:

- A Review of Lung Transplant Donor Acceptability Criteria (a consensus report of the ISHLT Pulmonary Council) <http://www.jhltonline.org/article/PIIS1053249803000962/fulltext>
- Primary Lung Graft Dysfunction Part III: Donor Related Risk Factors and Markers: <http://www.jhltonline.org/article/PIIS1053249805001348/fulltext>
- Donor Lung Procurement: <http://www.ctsnet.org/sections/clinicalresources/videos/media-81.html> (Cliff K. Choong, MD, Bryan F. Meyers, MD and G. Alexander Patterson, MD)
- Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the Present Status of Xenotransplantation and its Potential Role in the Treatment of End-Stage Cardiac and Pulmonary Diseases: http://www.isHLT.org/PDF/pdf_xeno_guidelines.pdf
- Organ donation information in Europe: <http://www.donoraction.org>
- U.S. government organ donation information site: <http://www.organdonor.gov>

Selected References for Lung Donation and Procurement:

- van Suylen V**, Luijk B, Hoek RAS, van de Graaf EA, Verschuuren EA, Van De Wauwer C, Bekkers JA, Meijer RCA, van der Bij W, Erasmus ME. A Multicenter Study on Long-Term Outcomes After Lung Transplantation Comparing Donation After Circulatory Death and Donation After Brain Death. *Am J Transplant*. 2017 May 4.
- Makdisi G**, Wozniak TC. How to establish a successful ex vivo lung perfusion program. *Ann Transl Med*. 2017 May;5(Suppl 1):S12.
- Martens A**, Van Raemdonck DE, Smits J, Verleden SE, Vos R, Vanaudenaerde BM, Verleden GM, Degezelle K, Desschans B, Neyrinck AP. A retrospective database analysis to evaluate the potential of EVLP to recruit declined lung donors. *Transpl Int*. 2017 May 27.
- Awori Hayanga JW**. Ex vivo lung perfusion: The makings of a game changer. *J Heart Lung Transplant*. 2017 Mar 7. pii: S1053-2498(17)31686-8.
- Slama A**, Schillab L, Barta M, Benedek A, Mitterbauer A, Hoetzenecker K, Taghavi S, Lang G, Matilla J, Ankersmit H, Hager H, Roth G, Klepetko W, Aigner C. Standard donor lung procurement with normothermic ex vivo lung perfusion: A prospective randomized clinical trial. *J Heart Lung Transplant*. 2017 Feb 20. pii: S1053-2498(17)31620-0.

Loor G, Howard BT, Spratt JR, Mattison LM, Panoskaltis-Mortari A, Brown RZ, Iles TL, Meyer CM, Helms H, Price A, Iazzo PA. Prolonged EVLP Using OCS Lung: Cellular and Acellular Perfusates. *Transplantation*. 2016 Dec 22.

Levin K, Kotecha S, Westall G, Snell G. How can we improve the quality of transplantable lungs? *Expert Rev Respir Med*. 2016 Oct 3:1-7.

Mulligan MJ, Sanchez PG, Evans CF, Wang Y, Kon ZN, Rajagopal K, Iacono AT, Gammie JS, Griffith BP, Pham SM. The use of extended criteria donors decreases one-year survival in high-risk lung recipients: A review of the United Network of Organ Sharing Database. *J Thorac Cardiovasc Surg*. 2016 Sep;152(3):891-898.e2.

Egan TM, Edwards LB. Effect of the lung allocation score on lung transplantation in the United States. *J Heart Lung Transplant*. 2016 Apr;35(4):433-9.

Noda K, Tane S, Haam SJ, Hayanga AJ, D'Cunha J, Luketich JD, Shigemura N. Optimal ex vivo lung perfusion techniques with oxygenated perfusate. *J Heart Lung Transplant*. 2017 Apr;36(4):466-474.

Fisher A, Andreasson A, Chrysos A, Lally J, Mamasoula C, Exley C, Wilkinson J, Qian J, Watson G, Lewington O, Chadwick T, McColl E, Pearce M, Mann K, McMeekin N, Vale L, Tsui S, Yonan N, Simon A, Marczin N, Mascaro J, Dark J. An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK. *Health Technol Assess*. 2016 Nov;20(85):1-276.

Yeung JC, Krueger T, Yasufuku K, de Perrot M, Pierre AF, Waddell TK, Singer LG, Keshavjee S, Cypel M. Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study. *Lancet Respir Med*. 2017 Feb;5(2):119-124.

Bremner RM. Rescue, revive, rejuvenate: The new science of ex vivo lung perfusion. *J Thorac Cardiovasc Surg*. 2017 Jan;153(1):205.

Schmack B, Weymann A, Mohite P, Garcia Saez D, Zych B, Sabashnikov A, Zerrouh M, Schamroth J, Koch A, Soresi S, Ananiadou O, De Robertis F, Karck M, Simon AR, Popov AF. Contemporary review of the organ care system in lung transplantation: potential advantages of a portable ex-vivo lung perfusion system. *Expert Rev Med Devices*. 2016 Nov;13(11):1035-1041.

Charles EJ, Huerter ME, Wagner CE, Sharma AK, Zhao Y, Stoler MH, Mehaffey JH, Isbell JM, Lau CL, Tribble CG, Laubach VE, Kron IL. Donation After Circulatory Death Lungs Transplantable Up to Six Hours After Ex Vivo Lung Perfusion. *Ann Thorac Surg*. 2016 Dec;102(6):1845-1853. doi: 10.1016/j.athoracsur.2016.06.043.

Wallinder A, Riise GC, Ricksten SE, Silverborn M, Dellgren G. Transplantation after ex vivo lung perfusion: A midterm follow-up. *J Heart Lung Transplant*. 2016 Nov;35(11):1303-1310.

Cypel M, Keshavjee S. Extracorporeal lung perfusion (ex-vivo lung perfusion). *Curr Opin Organ Transplant*. 2016 Jun;21(3):329-35.

Erasmus ME, van Raemdonck D, Akhtar MZ, Neyrinck A, de Antonio DG, Varela A, Dark J. DCD lung donation: donor criteria, procedural criteria, pulmonary graft function validation, and preservation. *Transpl Int*. 2016 Jul;29(7):790-7.

Reeb J, Cypel M. Ex vivo lung perfusion. *Clin Transplant*. 2016 Mar;30(3):183-94.

Mohamed MS. Ex Vivo Lung Perfusion and Transplant: State of the Art and View to the Future. *Exp Clin Transplant*. 2015 Dec;13(6):493-9.

Riddell P, Egan JJ. International donor conversion rates for lung transplantation need to be standardised. *Lancet Respir Med*. 2015 Dec;3(12):909-11.

Cypel M, Levvey B, Van Raemdonck D, Erasmus M, Dark J, Love R, Mason D, Glanville AR, Chambers D, Edwards LB, Stehlik J, Hertz M, Whitson BA, Yusen RD, Puri V, Hopkins P, Snell G, Keshavjee S; International Society for Heart and Lung Transplantation. International Society for Heart and Lung Transplantation Donation After Circulatory Death Registry Report. *J Heart Lung Transplant*. 2015 Oct;34(10):1278-82.

Campo-Cañaverl de la Cruz JL, Gómez de Antonio D, Hoyos-Mejía L, Pérez-Redondo M, Laporta-Hernández R, Varela de Ugarte A; Lung Transplant Unit of the Hospital Universitario Puerta de Hierro-Majadahonda. Controlled non-heart beating donor lung transplantation: initial experience in Spain. *Arch Bronconeumol*. 2015 Sep;51(9):e45-7.

Miyoshi K, Oto T, Konishi Y, Hirano Y, Okada M, Iga N, Hirayama S, Sugimoto S, Yamane M, Kobayashi M, Miyoshi S. Use of Extended-Criteria Lungs on a Lobe-by-Lobe Basis Through Ex Vivo Lung Perfusion Assessment. *Ann Thorac Surg*. 2015;99(5):1819-21.

Nathan SD, King CS. Organ Donors: Making the Most of What Is Offered. *Chest*. 2015 Aug;148(2):303-305. doi: 10.1378/chest.15-1269.

Egan TM, Requard JJ 3rd. Uncontrolled Donation After Circulatory Determination of Death Donors (uDCDDs) as a Source of Lungs for Transplant. *Am J Transplant*. 2015 Aug;15(8):2031-6.

Klesney-Tait J, Eberlein M, Geist L, Keech J, Zabner J, Gruber PJ, Iannettoni MD, Parekh K. Starting a lung transplant program: a roadmap for long-term excellence. *Chest*. 2015 May;147(5):1435-1443.

Fildes JE, Archer LD, Blaikley J, Ball AL, Stone JP, Sjöberg T, Steen S, Yonan N. Clinical Outcome of Patients Transplanted with Marginal Donor Lungs via Ex Vivo Lung Perfusion Compared to Standard Lung Transplantation. *Transplantation*. 2015 May;99(5):1078-83.

Machuca TN, Mercier O, Collaud S, Tikkanen J, Krueger T, Yeung JC, Chen M, Azad S, Singer L, Yasufuku K, de Perrot M, Pierre A, Waddell TK, Keshavjee S, Cypel M. Lung transplantation with donation after circulatory determination of death donors and the impact of ex vivo lung perfusion. *Am J Transplant*. 2015 Apr;15(4):993-1002.

Hayes D Jr, McConnell PI, Galantowicz M, Whitson BA, Tobias JD, Black SM. Outcomes in pediatric lung transplant recipients receiving adult allografts. *Ann Thorac Surg*. 2015 Apr;99(4):1184-91.

Tikkanen JM, Cypel M, Machuca TN, Azad S, Binnie M, Chow CW, Chaparro C, Hutcheon M, Yasufuku K, de Perrot M, Pierre AF, Waddell TK, Keshavjee S, Singer LG. Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation. *J Heart Lung Transplant*. 2015 Apr;34(4):547-56.

Elgharably H, Shafii AE, Mason DP. Expanding the donor pool: donation after cardiac death. *Thorac Surg Clin*. 2015;25(1):35-46.

Schaffer JM, Singh SK, Reitz BA, Zamanian RT, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. *JAMA*. 2015 Mar 3;313(9):936-48.

Cypel M, Keshavjee S. Extending the donor pool: rehabilitation of poor organs. *Thorac Surg Clin*. 2015;25(1):27-33. doi: 10.1016/j.thorsurg.2014.09.002.

Wigfield C. Donation after cardiac death for lung transplantation: a review of current clinical practice. *Curr Opin Organ Transplant*. 2014 Oct;19(5):455-9.

Sage E, Mussot S, Trebbia G, Puyo P, Stern M, Darteville P, Chapelier A, Fischler M; Foch Lung Transplant Group. Lung transplantation from initially rejected donors after ex vivo lung reconditioning: the French experience. *Eur J Cardiothorac Surg*. 2014 Nov;46(5):794-9.

Boffini M, Ricci D, Bonato R, Fanelli V, Attisani M, Ribezzo M, Solidoro P, Del Sorbo L, Ranieri VM, Rinaldi M. Incidence and severity of primary graft dysfunction after lung transplantation using rejected grafts reconditioned with ex vivo lung perfusion. *Eur J Cardiothorac Surg*. 2014 Nov;46(5):789-93.

Andreasson AS, Dark JH, Fisher AJ. Ex vivo lung perfusion in clinical lung transplantation--state of the art. *Eur J Cardiothorac Surg*. 2014 Nov;46(5):779-88.

Keating DT, Westall GP, Marasco SF, Burton JH, Buckland MR, Robertson CF, Williams TJ, Snell GI. Paediatric lobar lung transplantation: addressing the paucity of donor organs. *Med J Aust* 2008;189:173-175.

LUNG TRANSPLANTATION: SURGICAL AND POST-OPERATIVE MANAGEMENT

Learning Objectives for Lung Transplantation: Surgical and Post-Operative Management:

- 18) Understand the principles and practice of size matching between donor and recipient
- 19) Review the differential diagnosis and treatment strategies for graft failure in the early postoperative period
- 20) Discuss the management of pleural complications after lung transplantation
- 21) Understand the diagnostic and treatment strategies of bronchial, pulmonary artery and pulmonary venous complications
- 22) Understand the indications for, management of and contraindications to extracorporeal mechanical support after lung transplantation

1. **Immediate Post Transplant Management**

- a. Surgical Complications of Lung Transplant
- b. Medical Complications post Lung Transplantation
- c. Prophylactic Regimen (antibiotics, anti-fungal and anti-viral)

2. **Surgical Conduct**

- a. Size matching between donor and recipient
- b. Single versus double lung transplant
- c. Coordinating the timing of surgery
- d. Technical aspects of pneumonectomy
- e. Choice of incision- median sternotomy, bilateral anterior thoracotomy, clamshell, anterior vs posterolateral thoracotomy
- f. Use of cardiopulmonary bypass and intraoperative ECMO- disease specific, PAH
- g. Anastomotic techniques- running, interrupted, suture choice

3. **Postoperative Complications**

- a. Graft dysfunction- differential diagnosis and treatment (NO)
- b. Anastomotic
 - i. Airway- dehiscence, stenosis, bronchovascular fistula, stents
 - ii. Vascular- pulmonary vein and artery stenosis
- c. Pleural – acute and chronic effusions; empyema
- d. Renal Failure – prevention and treatment

4. **Special Considerations**

- a. Preoperative ECMO- VA vs VV. Criteria for listing and delisting, status 7.
- b. Postoperative ECMO- separation/weaning
- c. Combined cardiac surgery and lung transplantation. Stents vs CABG

Minimum Experience Requirement for Lung Transplantation: Surgical and Post-Operative Management:

UNOS Certification criteria for lung transplantation

- Participate in the matching of 15 or more lung transplant donors to recipients
- Participate in 15 or more operative and postoperative lung transplant managements.

Selected Hyperlinks for Lung Transplantation: Surgical and Post -Operative Management:

- <http://www.ctsnet.org/sections/clinicalresources/videos/media-90.html> (Cliff K. Choong, MD, Bryan F. Meyers, MD and G. Alexander Patterson, MD)
- <http://www.ctsnet.org/sections/clinicalresources/videos/media-80.html> (Cliff K. Choong, MD, Bryan F. Meyers, MD)

and G. Alexander Patterson, MD)

- Split lung transplantation with intraoperative extracorporeal membrane oxygenation (ECMO) support: <http://mmcts.ctsnetjournals.org/cgi/content/abstract/2005/0809/mmcts.2004.000984> (Gabriel Mihai Marta, Clemens Aigner and Walter Klepetko)
- Primary Lung Graft Dysfunction Part I: Introduction and Methods: <http://www.jhltonline.org/article/PIIS1053249805001889/fulltext>
- Primary Lung Graft Dysfunction Part II: Definition. A Consensus Statement of the International Society for Heart and Lung Transplantation: <http://www.jhltonline.org/article/PIIS1053249804006527/fulltext>
- Primary Lung Graft Dysfunction Part III: Donor Related Risk Factors and Markers: <http://www.jhltonline.org/article/PIIS1053249805001348/fulltext>
- Primary Lung Graft Dysfunction Part IV: Recipient-Related Risk Factors and Markers: <http://www.jhltonline.org/article/PIIS1053249805001361/fulltext>
- Primary Lung Graft Dysfunction Part V: Predictors and Outcomes: <http://www.jhltonline.org/article/PIIS1053249804010526/fulltext>
- Primary Lung Graft Dysfunction Part VI: Treatment: <http://www.jhltonline.org/article/PIIS1053249805001956/fulltext>

Selected References for Lung Transplantation: Surgical and Post-Operative Management:

Kogan A, Ilgaev N, Sahar G, et al. Atrial fibrillation after adult lung transplantation. *Transplant Proc* 2003;35(2):679.

Boffa DJ, Mason DP, Su JW, et al. Decortication after lung transplantation. *Ann Thorac Surg* 2008;85(3):1039-43.

Herridge MS, de Hoyos AL, Chaparro C, Winton TL, Kesten S, Maurer JR. Pleural complications in lung transplant recipients. *J Thorac Cardiovasc Surg* 1995;110(1):22-6.

Chakinala MM, Trulock EP. Acute allograft rejection after lung transplantation: diagnosis and therapy. *Chest Surg Clin N Am* 2003;13(3):525-42.

Ferretti G, Boutelant M, Thony F, Carpentier F, Pison C, Guignier M. Successful stenting of a pulmonary arterial stenosis after a single lung transplant. *Thorax* 1995;50(9):1011-2; discussion 6-7.

Mason DP, Solovera-Rozas M, Feng J, et al. Dialysis after lung transplantation: prevalence, risk factors and outcome. *J Heart Lung Transplant* 2007;26(11):1155-62.

Bavaria JE, Kotloff R, Palevsky H, et al. Bilateral versus single lung transplantation for chronic obstructive pulmonary disease. *J Thorac Cardiovasc Surg* 1997;113(3):520-7; discussion

Davis RD, Jr., Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. *J Thorac Cardiovasc Surg* 2003;125(3):533-42.

Hadjiliadis D, Angel LF. Controversies in lung transplantation: are two lungs better than one? *Semin Respir Crit Care Med* 2006;27(5):561-6.

Pochettino A, Kotloff RM, Rosengard BR, et al. Bilateral versus single lung transplantation for chronic obstructive pulmonary disease: intermediate-term results. *Ann Thorac Surg* 2000;70(6):1813-8; discussion 8-9.

Kozower BD, Meyers BF, Smith MA, et al. The impact of the lung allocation score on short-term transplantation outcomes: a multicenter study. *J Thorac Cardiovasc Surg* 2008;135(1):166-71.

Wang Y, Kurichi JE, Blumenthal NP, et al. Multiple variables affecting blood usage in lung transplantation. *J Heart Lung Transplant* 2006;25(5):533-8.

Hachem RR. Lung allograft rejection: diagnosis and management. *Curr Opin Organ Transplant* 2009;14(5):477-82.

IV. REJECTION AFTER LUNG TRANSPLANTATION, IMMUNOSUPPRESSION PROTOCOLS AND COMPLICATIONS

A. IMMUNOLOGIC CONCEPTS IN LUNG TRANSPLANTATION

Learning Objectives for Immunologic Concepts in Lung Transplantation

- 23) Review the general concepts and definitions of Basic Immunology
- 24) Recognize the roles of lymphocytes responsible for immune responses (B v T cells)
- 25) Discuss the different types of rejection and each of their proposed mechanisms
- 26) List the causes of HLA allo-immunization
- 27) Understand the differences in the tests involved in the evaluation of the immune work up prior to transplantation

1. Definitions

2. Normal Immune Response

- a. Innate vs Adaptive Immune System
- b. Molecules and cells of the immune system
 - i. T cells
 - ii. B cells
 - iii. NK cells
- c. Response to foreign antigen

3. Immune Response to Allograft

- a. Mechanism of allorecognition
- b. Humoral vs Cellular Rejection
- c. Proposed mechanism of each type of allograft rejection:
 - i. Hyperacute rejection
 - ii. Acute rejection
 - iii. Chronic rejection
 - iv. Humoral rejection

4. Tolerance

- a. Definition
- b. Mechanisms
- c. Clinical Implications

5. Immunogenetics

- a. ABO Blood System
- b. Major Histocompatibility Complex I and II
 - i. HLA Nomenclature and HLA genetics
 - ii. Causes of HLA-specific alloimmunization
 - iii. HLA Antigen Matching in Lung Transplantation
- c. Methods used to detect anti-HLA antibodies
 - i. Calculated PRA (c-PRA), Virtual Crossmatch
 - ii. Detection of presence of anti-HLA antibodies
 - iii. Panel reactive antibodies
 - iv. Complement Dependent Cytotoxicity (CDC)
 - v. Flow Cytometry
 - vi. Solid Phase Assays
 - 1. Luminex
 - 2. Flow Cytometry
 - 3. ELISA
 - vii. Screening strategies

6. **Non-HLA Antigens**

7. **Clinical Applications of Transplant Immunology and Typing**

8. **The Sensitized Recipient**

- a. Screening: Types of screening pre-transplant
 - i. PRA
 - ii. V-PRA
 - iii. Single Antigen / antibody testing
- b. Management of the sensitized patient
 - i. Treatment and monitoring prior to transplantation
 - ii. Treatment and monitoring peri-operatively and post-transplant
- c. Risks

Minimum Experience Requirement for Immunologic Concepts in Lung Transplantation:

- Participate in evaluation of the immunologic work up along with immunologist of 15 patients being evaluated for transplantation.

Selected References for Immunologic Concepts in Lung Transplantation:

Hale, D. Surg Clin N Am 86 (2006) 1103-1125.

Teasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3 (6) 665-73.

Delves PJ et al. The immune system. First of two parts. N Engl J Med 2000; 343: 37-49.

Delves PJ et al. The immune system. Second of two parts. N Engl J Med 2000; 343: 108-17.

Tambur AR et al. Transplantation 2008; 86: 1052-1059

Fuggle SV et al. Tools for Human Leukocyte Antigen Antibody Detection and Their Application to Transplanting Sensitized Patients. Transplantation: 2008; 86: 384-390.

Marsh SGE et al. Nomenclature for factors of the HLA system. Eur J Immunogenet 2002; 29: 463-5158.

Ramachandran FN et al. Antibodies to MHC class I induce autoimmunity. J Immunol 2009; 182-309-318.

Neuringer P et al. Obliterative Bronchiolitis or Chronic Lung Allograft Rejection: A Basic Science Review. J Heart Lung Transplant 2005;24:3-19.

B. REJECTION IN THE LUNG TRANSPLANT RECIPIENT

Learning Objectives for Rejection in the Lung Transplant Recipient:

- 28) Define the different types of lung transplant rejection
- 29) Discuss the diagnostic approaches to evaluation for each of the different types of rejection post-transplant
- 30) Discuss surveillance bronchoscopy and pros and cons
- 31) Define acute cellular rejection per the ISHLT guidelines
- 32) List the risk factors and outcomes for BOS (chronic rejection)
- 33) Outline the timeline each type of rejection
- 34) Understand significance of the sensitized patient
- 35) Review the histological differences between acute and chronic rejection
- 36) Explain the treatment options for patients with BOS

1. **Hyperacute Rejection**

- a. Definition
- b. Mechanism
- c. Pathology
- d. Treatment

2. **Acute Cellular Rejection**

- a. Definition-(ISHLT guidelines)
- b. Detection, Evaluation and Diagnosis

- i. Surveillance bronchoscopy
 - 1. Pros and Cons
 - 2. Table of possible surveillance schedules
 - ii. Monitoring
 - 1. Spirometry
 - 2. Clinical status
 - 3. Bronchoscopy
 - 4. Radiographic changes
 - c. Grading of acute cellular rejection
 - i. ISHLT Pathologic grading
 - d. Type of ACR
 - i. Recurrent
 - ii. Refractory
 - iii. Lymphocytic bronchiolitis
 - e. Treatment Options
 - i. Modified immunosuppression regimen
 - 1. Steroid pulse and taper
 - 2. Change calcineurin inhibitor
 - 3. Alemtuzumab, antithymocyte globulin, ECP,
 - 4. Others
 - f. Outcomes
 - g. Clinical Implications
 - h. Risk Factors

3. **Humoral or Antibody-Mediated Rejection**

- a. Definition
- b. Evaluation, Screening and Diagnosis
 - i. Serologic
 - ii. Pathologic
 - iii. Immunologic
- c. Monitoring
 - i. Donor specific antibodies
 - ii. C4d monitoring
- d. Treatment Options
- e. Outcomes

Risk Factors

4. **Chronic Lung Allograft Dysfunction (CLAD)**

- a. Update in our understanding of CLAD
- b. Obstructive CLAD: Bronchiolitis Obliterans
 - i. Clinical presentation
 - ii. Spirometric Diagnosis
 - iii. Pathologic diagnosis
 - iv. Radiographic findings
 - v. Grading (ISHLT guidelines)
 - vi. Prognosis
- c. Restrictive CLAD:
 - i. Clinical presentation
 - ii. Spirometric Findings
 - iii. Radiographic Findings
 - iv. Pathologic diagnosis
 - v. Prognosis
- d. Treatment Options
 - i. Photophoresis
 - ii. Azithromycin
 - iii. Augment or change immunosuppression
 - iv. Re-transplantation

- e. Risk Factors
 - i. Acute cellular rejection (ACR)
 - ii. Lymphocytic bronchitis/bronchiolitis (LB)
 - iii. Organizing pneumonia
 - iv. HLA mismatch
 - v. GERD
 - vi. CMV/respiratory viruses
 - vii. Primary Graft Dysfunction (PGD)

Minimum Experience Requirement for Rejection in the Lung Transplant Recipient:

- Review the slides of at least 10 patients with pathologist with acute cellular rejection.
- Diagnose and treat at least 10 patients with acute cellular rejection, humoral rejection and bronchiolitis obliterans syndrome (BOS).
- Perform at least 10 bronchoscopies post transplant to evaluate for ACR.

Selected References for Rejection in the Lung Transplant Recipient:

- Roden AC et al.** Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies: A Perspective From Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med.* 2017;141(3):437-444
- Levine DJ et al.** Antibody-mediated rejection of the lung: A consensus report of the ISHLT. *J Heart Lung Transplant* 2016;35:397-406
- Royer PJ et al.** Chronic Lung Allograft Dysfunction: A systematic Review of Mechanisms. *Transplantation* 2016;100(9):1803-14
- Tikkanen JM, Singer LG, Kim SJ, Li Y, Binnie M, Chaparro C, Chow CW, Martinu T, Azad S, Keshavjee S, Tinckam K.** De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation. *Am J Respir Crit Care Med.* 2016 Sep 1;194(5):596-606.
- Gauthier JM et al.** Update on Chronic Lung Allograft Dysfunction. *Curr Transplant Rep* 2016;3(3):185-191
- Tinckam KJ et al.** Survival in Sensitized Lung Transplant Recipients with Perioperative Desensitization. *Am J Transplant* 2015;15:417-426
- Westall GP et al.** Antibody-mediated Rejection. *Curr Opin Organ Transplant* 2015;20(5):492-7
- Verleden GM et al.** A new classification system for chronic lung allograft dysfunction. *J Heart Lung Transplant* 2014;33(2):127-33
- Snyder LD et al.** Antibody Desensitization Therapy in Highly Sensitized Lung Transplant Candidates. *Am J Transplant* 2014;14:849-856
- Meyer KC et al.** An International ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. *Euro Resp J* 2014;44:1479-1503
- Sandrini A et al.** The controversial role of surveillance bronchoscopy after lung transplantation. *Curr Opin Organ Transplant.* 2009 Oct;14(5):494-8.
- Martinu T et al.** Acute Rejection and Humoral Sensitization in Lung Transplant Recipients. *Proc Am Thorac Soc*
- Belperio JA et al.** Chronic Lung Allograft Rejection : mechanisms and Therapy: *Proc Am Thorac* 2009: vol 6: 108-121.
- McWilliams TJ et al.** Surveillance bronchoscopy in lung transplant recipients: risk versus benefit. *J Heart Lung Transplant* 2008; 27:1203–1209.
- Benden C et al.** Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. *Transplantation* 2008; 86:1625–1627.
- Stewart S et al.** Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. *J Heart Lung Transplant* 2007; 26:1229–1242
- Nicod LP.** Mechanisms of airway obliteration after lung transplantation. . *Proc Am Thorac Soc.* 2006 (5):444-9.
- Christie et al:** The effect of primary graft dysfunction on survival after lung transplantation, *Am J Respir Crit Care Med* 2005;171:1312–1316
- Yates B et al.** Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. *Am J Respir Crit Care Med* 15 2005;172:772–5.
- Davis RD et al.** Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. *J Thorac Cardiovasc Surg* 2003;125:533–42.
- Kumar, et al.** Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. *Am J Transplant* 2005;5:2031–6.
- Sharples et al.** Risk factors for bronchiolitis obliterans: a systematic review of recent publications. *J Heart Lung Transplant* 2002;21:271–81.

C. IMMUNOSUPPRESSION REGIMENS POST LUNG TRANSPLANTATION

Learning Objectives for Immunosuppression Regimens Post Lung Transplantation:

- 37) Discuss the triple agent immunosuppression protocol and which types of agents are typically used
- 38) Understand the side effects of each of the drug classes
- 39) Describe the monitoring of levels of the calcineurin inhibitors and what range of levels is appropriate
- 40) List the possible complications of induction therapy
- 41) Discuss the laboratory tests to order to evaluate toxicity from the different classes of drugs

42) Discuss drug-drug interactions with the calcineurin inhibitors

1. Overview of Immunosuppressive Agents

- a. Immunosuppressant Action and the Immune Cascade (how all of the agents relate within the cascade where the agent affects the immunologic process).
- b. Induction Agents
- c. Primary Immunosuppressants
- d. Adjuvant agents
- e. Induction
 - i. Risks and Benefits
 - ii. Agents (For all agents: target, indication, dose, administration, adverse events, monitoring)
 1. Basiliximab (Anti-IL-2)
 2. Alemtuzumab (Anti CD-52)
 3. Thymoglobulin (rATG)
 4. OKT3 (anti-Cd-3)
- f. Maintenance
 - i. Triple Agent Immunosuppression Regimen
 - ii. Corticosteroids
 1. Mechanism of action
 2. Pharmacokinetics, dosing and drug monitoring
 3. Side effects
 4. Drug-drug interactions
 - iii. Calcineurin Inhibitors (Cyclosporine and Tacrolimus)
 1. Mechanism of action
 2. Pharmacokinetics, dosing and drug monitoring
 3. Side effects
 4. Drug-drug interactions
 - iv. Anti-proliferative agents (Azathioprine and Mycophenolic acid (MMF))
 1. Mechanism of action
 2. Pharmacokinetics, dosing and drug monitoring
 3. Side effects
 4. Drug-drug interactions
 - v. TOR inhibitors (Sirolimus and Everolimus)
 1. Mechanism of action
 2. Pharmacokinetics, dosing and drug monitoring
 3. Side effects
 4. Drug-drug interactions
- g. Rejection
 - i. Acute Cellular Rejection
 1. Augmentation of Maintenance Therapy
 2. Adjustment of Maintenance Therapy
 - ii. Chronic Lung Allograft Dysfunction
 1. Augmentation of Maintenance Therapy
 2. Adjustment of Maintenance Therapy
 3. Azithromycin
 - iii. Humoral Rejection
 1. Plasmapheresis
 2. IVIG
 3. Rituximab
 4. Bortezomib or Carfilzomib
- h. Trends and Issues in Immunosuppression
- i. Salvage Therapy for Chronic Rejection
 - i. Total lymphoid Irradiation (TLI)
 - ii. Extracorporeal Photopheresis (ECP)
- j. Desensitization
 - i. Plasmapheresis
 - ii. IVIG
 - iii. Rituximab

iv. Bortezomib or Carfilzomib

Minimum Experience Required for Immunosuppression Regimens Post Lung Transplantation:

- Treat 15 patients with immunosuppression post lung transplant and adjust changes and following for side effects or drug interactions.

Selected Hyperlinks for Immunosuppression Regimens Post Lung Transplantation:

- Generic Drug Immunosuppression in Thoracic Transplantation: An ISHLT Educational Advisory: https://www.isHLT.org/ContentDocuments/JHLT_July2009_Generic_Concensus_Statement.pdf

Selected References for Immunosuppression Regimens Post Lung Transplantation:

- Taylor A.** Immunosuppressive agents in solid organ transplantation: Critical Reviews in Oncology/Hematology 56 (2005) 23–46.
- Hallora PF.** Immunosuppressive Drugs for Kidney Transplantation. N Engl J Med 2004;351:2715-29.
- Bhorade S et al.** Immunosuppression for Lung Transplantation Proc Am Thorac Soc Vol 6. pp 47–53, 2009
- McNeil K et al.** . Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006;81:998–1003
- Ailawadi G et al.** Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. J Thorac Cardiovasc Surg 2008;135:594–602.
- Hachem R et al.** A comparison of basiliximab and antithymocyte globulin as induction agents after lung transplantation. J Heart Lung Transplant 2005;24:1320–1326.
- Burton et al.** . The incidence of acute cellular rejection after lung transplantation: a comparative study of antithymocyte globulin and daclizumab. J Heart Lung Transplant 2006;25: 638–647.
- Diamond D et al.** Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation. Int J Radiat Oncol Biol Phys 1998;41:795–800.
- Slovic B et al.** . Photopheresis for chronic rejection of lung allografts. N Engl J Med 1995;332:962.
- Salerno C et al.** Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. J Thorac Cardiovasc Surg 1999;117:1063–1069.
- Villanueva J, Bhorade SM, Robinson JA, Husain AN, Garrity ER Jr.** Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 2000;5:44–47.
- Sweet SC.** Induction therapy in lung transplantation. Transplant International. 2013;26:696-703
- Treed H et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant 2012;31(8):797-804
- Glanville AR et al.** Mycophenolate Mofetil (MMF) vs Azathioprine (AZA) in lung transplantation for the prevention of Bronchiolitis Obliterans Syndrome (BOS): results of a 3 year international randomized trial. 2003;22(1):S207

D. HEMATOLOGIC DISORDERS POST LUNG TRANSPLANTATION

Learning Objectives for Hematologic Disorders Post Lung Transplantation

- 43) List the major causes of leukopenia post lung transplantation
- 44) Understand treatment options for drug-induced penias
- 45) Discuss the reasons for anemia post lung transplantation

1. **Thrombocytopenia**

- a. Evaluation and Diagnostic work up
- b. Medication effect (including immunosuppression and antimicrobial therapies)
- c. Infection
- d. Treatment options

2. **Anemia**

- a. Evaluation and Diagnostic Work up
- b. Medication effect / Drug Reaction(Immunosuppressive or antimicrobials)
- c. Infection
- d. Iron deficiency
- e. HUS
- f. Treatment options

3. **Leukopenia or Leukocytosis**

- a. Evaluation and Diagnostic Work up
- b. Medication effect / Drug Reaction
- c. Infection
- d. Treatment Options

Minimum Experience Requirement for Hematologic Disorders Post Lung Transplantation:

- Evaluate, monitor and treat 10 patients with leukopenia, thrombocytopenia or anemia post transplant.

E. GASTROINTESTINAL ISSUES POST LUNG TRANSPLANTATION

Learning Objectives for Gastrointestinal Issues Post Lung Transplantation

- 46) Discuss the risk factors for bowel perforation post lung transplantation
- 47) Understand the significance of GERD in lung transplant recipients and its association with BOS (chronic rejection)
- 48) Identify the gastrointestinal issues that are important to Cystic Fibrosis patients who undergo lung transplantation
- 49) Understand the etiologies behind the common gastrointestinal symptoms patients have post lung transplantation
- 50) Discuss the different anti-infective and immunosuppressive agents that typically are associated with gastrointestinal side effects and liver toxicity

1. Frequent Problems and their Possible Etiologies

- a. Nausea/Vomiting
 - i. Medications
 - ii. Infection
 - iii. Gastroparesis/delayed gastric emptying
 - iv. Small bowel obstruction or ileus
 - v. GERD
- b. Diarrhea
 - i. Medications
 - ii. Infection: C. difficile, protozoa, viral, bacterial
 - iii. CMV Colitis
 - iv. Ischemic Colitis
 - v. Prior co-morbidities
- c. Abdominal Pain

2. Colonic Issues

- a. Bowel Perforation : multiple risks and etiologies
- b. Diverticulitis/diverticulosis
- c. PTLD/Malignancy
- d. Colitis (viral, fungal or ischemic)
- e. Pseudomembranous colitis and C. Difficile

3. Small Bowel Obstruction

- a. Gastroparesis
- b. PTLD
- c. Constipation

4. Upper Gastrointestinal Issues

- a. Gastroparesis
- b. Esophagitis
- c. PUD
- d. GERD

5. GERD and BOS

6. GI Bleed

- a. Peptic Ulcer Disease
- b. Esophagitis

- i. Candidiasis or fungal
- ii. Malignancy
- iii. CMV or viral

7. Biliary Disease

- a. Cholelithiasis pre-transplant
 - i. Timing for cholecystectomy
- b. Cholecystitis

8. Pancreatitis

- a. Infection
- b. Medication: Cyclosporine, Azithiprine, Prednisone

9. GI Complications of Cystic Fibrosis Patients

- a. DIOS
- b. Pancreatitis
- c. Cholecystitis
- d. Bowel obstruction

10. Hepatic Toxicity Secondary to Medication

11. Hyperammonemia

Selected References Gastrointestinal Issues Post Lung Transplantation:

- Young LR**, Hadjiiladis D, Davis RD, Palmer SM. Lung transplantation exacerbates gastroesophageal reflux disease. *Chest* 2003;124:1689–1693.
- Gilljam M**, et al. GI complications after lung transplantation in patients with cystic fibrosis. *Chest* 2003;123:37–41.
- Paul S**. et al. Heart Lung Transplant. Gastrointestinal complications after lung transplantation 2009 May;28(5):475-9.
- Matthew G** et al. Antireflux Surgery in the Setting of Lung Transplantation: Strategies for Treating Gastroesophageal Reflux Disease in a High-Risk Population. *Thoracic Surgery Clinics - Volume 15, Issue 3 (August 2005)*
- Robertson AG** et al. Lung transplantation, gastroesophageal reflux, and fundoplication. *Ann Thorac Surg.* 2010 Feb;89(2):653-
- Goldberg HJ** et al. Colon and rectal complications after heart and lung transplantation. *J Am Coll Surg* 2006;202:55–61.
- Morton JR** Distal intestinal obstruction syndrome (DIOS) in patients with cystic fibrosis after lung transplantation. *J Gastrointest Surg.* 2009 Aug;13(8):1448-53. Epub 2009 May 22.
- Corris PA**. Lung transplantation for cystic fibrosis. *Curr Opin Organ Transplant.* 2008 Oct;13(5):484-8.
- Bharat A et al**. Disseminated Ureaplasma infection as a cause of fatal hyperammonemia. *Science Translational Medicine* 2015;7(284):1-7

V. Lung Transplantation Pathology

Learning Objectives for Lung Transplantation Pathology:

- 51) To recognize the common indications and histopathological patterns in combined heart-lung, single lung and double lung transplantation
- 52) To understand the common pathological complications utilizing a temporal approach
- 53) To recognize the histopathological grades of acute cellular rejection
- 54) To understand the current diagnostic challenges of acute antibody mediated rejection
- 55) To describe the patterns and causes of airway inflammation
- 56) To recognize the histopathological findings in chronic airway and vascular rejection
- 57) To outline the pulmonary diseases that can recur in the lung allograft

1. Pathology of Common Indications for Thoracic Transplantation

- a. Congenital Heart Disease/Eisenmenger's Syndrome
- b. Cystic Fibrosis
- c. Primary Pulmonary Hypertension
- d. Chronic Obstructive Lung Disease
- e. Idiopathic Pulmonary Fibrosis

2. Specimen Adequacy and Handling

- a. Transbronchial Biopsy
 - i. Number of Tissue Samples for Adequacy
 - ii. Tissue Handling and Fixation
 - iii. Processing of Urgent vs. Routine Biopsy
 - iv. Basic/Routine Staining
 - v. Immunohistochemical/Molecular Studies
- b. Bronchioloalveolar Lavage
- c. Endobronchial Biopsy
- d. Video-Assisted Thoracoscopic Biopsy (VATS)

3. Post-Operative and Immediate Post-Transplant Graft Dysfunction (Within 7 days)

- a. Definition
- b. Surgical Technical Complications
 - i. Arterial/Venous Obstruction
 - ii. Airway Dehiscence/Obstruction
- c. Preservation Injury/Reimplantation Response
 - i. Definition
 - ii. Histopathological Findings
- d. Hyperacute Rejection
 - i. Definition
 - ii. Histopathological Findings
 - iii. Immunohistochemical/Immunofluorescent Findings
- e. Infection
 - i. Bacterial
 - ii. Viral
 - iii. Fungal
 - iv. Other

4. Early Complications Following Lung Transplantation (1 week – 6 months)

- a. Definitions
- b. Classification
- c. Diagnostic Techniques

5. Acute Cellular Rejection (ACR)

- a. Definition

- b. Grading of ACR
 - i. Minimal
 - ii. Mild
 - iii. Moderate
 - iv. Severe
- c. Morphological Mimics of ACR
 - i. Bronchial-Associated Lymphoid Tissue (BALT)
 - ii. Infection
 - iii. Post-Transplant Lymphoproliferative Disorder

6. Infections in Lung Allograft

- a. Bacterial
- b. Viral
- c. Fungal
- d. Parasitic/Protozoan

7. Acute Antibody Mediated/Humoral Rejection (AMR)

- a. Definitions
- b. Histopathological Findings
- c. Immunohistochemical/Immunofluorescent Findings
- d. Ongoing Issues and Controversies

8. Airway Inflammation/Lymphocytic Bronchitis/Bronchiolitis

- a. Definition
- b. Histopathological features
- c. Grading of Acute Airway Rejection
 - i. Low Grade
 - ii. High Grade
- d. Morphological Mimics
 - i. Airway Inflammation Associated with AMR
 - ii. Bronchus-Associated Lymphoid Tissue (BALT)
 - iii. Prior Biopsy Site
 - iv. Ischemic Injury/Organizing Pneumonia
 - v. Aspiration Injury
 - vi. Infection

9. Post-Transplant Lymphoproliferative Disorder (PTLD)

- a. Definition
- b. Histopathological Patterns
- c. Immunohistochemical/Molecular Markers
- d. Role of EBV Infection
- e. Other EBV-associated Proliferations

10. Late Complications (Beyond 6 months)

- a. Definition
- b. Classification
- c. Diagnostic Techniques

11. Chronic Airway Rejection (CAR)

- a. Definition
- b. Histopathological Findings
- c. Grading of CAR
- d. Role of Transbronchial Biopsy
- e. Differential Diagnosis
 - i. Organizing Pneumonia
 - ii. Prior Biopsy Site
 - iii. Aspiration

12. **Chronic Vascular Rejection (CVR)**

- a. Definition
- b. Histopathological Findings

13. **Recurrence of Native/Primary Lung Disease**

- a. Sarcoidosis
- b. Lymphangioleiomyomatosis (LAM)
- c. Diffuse Panbronchiolitis
- d. Giant Cell Interstitial Pneumonia (GIP)
- e. Desquamative Interstitial Pneumonia (DIP)
- f. Langerhans-Cell Histiocytosis
- g. Adenocarcinoma

Selected References for Lung Transplantation Pathology:

Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. *J Heart Lung Transplant* 2007;26:129-1242.

Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. *Springer Semin Immunopathol* 2003;25:119-140.

Wallace WD, Reed EF, Ross D, et al. C4d staining of pulmonary allograft biopsies: an immunohistochemical study. *J Heart Lung Transplant* 2005;24:1565-1570.

Revision of the 1990 Working Formulation for the Classification of Pulmonary Allograft Rejection: Lung Rejection Study Group. Members of the Pulmonary Pathology Society. *Arch Pathol Lab Med.* 2017;141(3):437-444.

Levine DJ et al. Antibody-mediated rejection of the lung: A consensus report of the ISHLT. *J Heart Lung Transplant* 2016;35:397-406

Kremer BE et al. Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases. *J Heart Lung Transplant* 2012;31(3):296-304

VI. DIAGNOSIS AND MANAGEMENT OF INFECTIONS FOLLOWING LUNG TRANSPLANTATION

Learning Objectives for Diagnosis and Management of Infections Following Lung Transplantation:

- 58) To highlight the specific components of innate and alloimmunity integral to host immunity to infection in the lung, and the impact of corticosteroids, calcineuren inhibitors, cell cycle inhibitors, and T-cell depleting agents on the immune response in the allograft.
- 59) To outline the comprehensive approach to evaluating immunity and pulmonary/ non-pulmonary infections in the lung transplant candidate.
- 60) To discuss the significance and evaluation of infections in the lung donor.
- 61) To demonstrate the impact of the surgical disruption of the normal pathways of innate lung immunity on the development of infection in the lung transplant recipient.
- 62) To describe the timeline, diagnostic methods, prophylaxis, and management of specific early and late post-transplant infections.
- 63) To develop a strategy for recognizing the most common and most challenging bacterial, fungal, and viral pathogens that infect lung transplant recipients.
- 64) To list the potential non-infectious allograft sequelae resulting from infectious pathogens.

1. Immune Response to Infection

- a. Components of the Immune Response to Infection
 - i. Cell Types
 - ii. Antibodies
 - iii. Complement
 - iv. T cell receptors and MHC molecules
- b. Components specific to immune response to infection in the lung
 - i. Innate Immunity
 - ii. Cellular Immunity
 - iii. Humoral Immunity
- c. Immunity Against Specific Infectious Agents
 - i. Immunity to Viruses
 - ii. Immunity to Bacteria
 - iii. Immunity to Fungi
 - iv. Immunity to Parasites
- d. Impact of Immunosuppression on Immune Response to Infection
 - i. Corticosteroids
 - ii. Calcineurin Inhibitors
 - iii. Cell Cycle Inhibitors
 - iv. T-Cell Depleting Agents

2. Evaluation of Infection in the Pre-Transplant Candidate

- a. Evaluation of Immunity to Infection
 - i. History of Infections
 - ii. Serologic Testing
 - iii. Immunoglobulin Testing
 - iv. Vaccinations
- b. Approach to Evaluation of Airway Colonization/Infection
 - i. History of Infection
 - ii. Diagnostic Modalities
 1. Computed Tomography
 2. Sputum vs BAL
 3. Use of Synergy and Multiple Antibiotic Sensitivity Testing
 - iii. Specific Pathogens
 1. Gram Negative Bacteria
 2. Fungi

- 3. Mycobacteria
- 4. Burkholderia Cepacia
- c. Evaluation for Non-Pulmonary Infections
 - i. Hepatitis B and C
 - ii. HIV

3. **Significance of Infections in the Donor**

- a. Diagnostic Approach
 - i. History
 - ii. Serologic Testing
 - iii. BAL Gram Stain
- b. Impact of Donor Infections on Early Allograft Function
 - i. Bacterial and fungal pathogens
 - ii. Viral pathogens
 - 1. CMV
 - 2. EBV
 - 3. Community **acquired** viruses
- c. Impact of Donor Infections on Allograft Prophylaxis Strategies

4. **Impaired Physiologic Mechanisms in the Allograft and Impact on Infection**

- a. Donor-specific Mechanisms
 - i. Neurogenic edema
 - ii. Ischemic Injury
 - iii. Reperfusion Injury
- b. Surgical Disruption of Normal Pathways of Innate Immunity
 - i. Lymphatic Drainage
 - ii. Atelectasis
 - iii. Surfactant Depletion
 - iv. Mucociliary Apparatus
 - v. Airway Neural Denervation/ Loss of Cough Reflex

5. **Overview and Timeline of Infections Following Lung Transplantation**

6. **Bacterial Infections**

- a. Prophylaxis and Treatment of Bacterial Pneumonia

7. **Atypical Mycobacterial Infections and Nocardia**

- a. Tuberculosis, including donor derived
- b. M. abscessus
- c. Mycobacterium avium
- d. Nocardia

8. **Fungal Infections**

- a. Anti-Fungal Prophylaxis
- b. Aspergillus
- c. Mucor / Rhizopus
- d. Scedosporium
- e. Endemic Fungal infections (Coccidioides, Histoplasma, etc.)

9. **Viral Infections**

- a. CMV
 - i. Prophylaxis vs. Pre-emptive therapy
 - ii. Disease Manifestations
 - iii. Resistant disease
 - iv. Implications
- b. Respiratory Viral Infections
 - v. RSV
 - vi. Others

10. Non-Infectious Allograft Sequelae of Infectious Pathogens

- a. EBV and the Development of PTLD
- b. CMV and the Development of BOS
- c. Community **Acquired** Respiratory Viruses and the Development of Acute Rejection and BOS
- d. Fungal and Bacterial Infections and Anastomotic Complications

11. Immune Monitoring and Infection

- a. Immunosuppressive Drug Levels
- b. Viral DNA
 - i. EBV
 - ii. CMV

Selected Hyperlinks:

- [The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary](http://www.jhltonline.org/article/S1053-2498(16)00054-1/pdf) (Guidelines) J Heart Lung Transplant Vol 35, No 3, March 2016: [http://www.jhltonline.org/article/S1053-2498\(16\)00054-1/pdf](http://www.jhltonline.org/article/S1053-2498(16)00054-1/pdf)
- [A 2010 Working Formulation for the Standardization of Definitions of Infections in Cardiothoracic Transplant Recipients](http://www.jhltonline.org/article/S1053-2498(11)00731-5/pdf) (Consensus Document) J Heart Lung Transplant 2011;30:361-374. [http://www.jhltonline.org/article/S1053-2498\(11\)00731-5/pdf](http://www.jhltonline.org/article/S1053-2498(11)00731-5/pdf)

Selected References for the Diagnosis and Management of Infections Following Lung Transplantation:

- Fisher CE**, Preiksaitis CM, Lease ED, Edelman J, Kirby KA, Leisenring WM, Raghu G, Boeckh M, Limaye AP. Symptomatic Respiratory Virus Infection and Chronic Lung Allograft Dysfunction. Clin Infect Dis. 2016 Feb 1;62(3):313-319.
- De Vlamincck I**, Martin L, Kertesz M, Patel K, Kowarsky M, Strehl C, Cohen G, Luikart H, Neff NF, Okamoto J, Nicolls MR, Cornfield D, Weill D, Valantine H, Khush KK, Quake SR. Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13336-41.
- Gottlieb J**, Zamora MR, Hodges T, Musk AW, Sommerwerk U, Dilling D, Arcasoy S, DeVincenzo J, Karsten V, Shah S, Bettencourt BR, Cehelsky J, Nochur S, Gollob J, Vaishnav A, Simon AR, Glanville AR. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016 Feb;35(2):213-21.
- Burrows FS**, Carlos LM, Benzimra M, Marriott DJ, Havryk AP, Plit ML, Malouf MA, Glanville AR. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency. J Heart Lung Transplant. 2015 Jul;34(7):958-62.
- Lee JT**, Kelly RF, Hertz MI, Dunitz JM, Shumway SJ. Clostridium difficile infection increases mortality risk in lung transplant recipients. J Heart Lung Transplant. 2013 Oct;32(10):1020-6.
- Lee JT**, Hertz MI, Dunitz JM, Kelly RF, D'Cunha J, Whitson BA, Shumway SJ. The rise of Clostridium difficile infection in lung transplant recipients in the modern era. Clin Transplant. 2013 Mar-Apr;27(2):303-10.
- Knoll BM**, Kappagoda S, Gill RR, Goldberg HJ, Boyle K, Baden LR, Fuhlbrigge AL, Marty FM. Non-tuberculous mycobacterial infection among lung transplant recipients: a 15-year cohort study. Transpl Infect Dis. 2012 Oct;14(5):452-60.
- Li L**, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012 Aug;31(8):839-44.
- Wiita AP**, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis. 2012 Jun;14(3):248-58.
- Snyderman DR**, Limaye AP, Potena L, Zamora MR. Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc. 2011 Apr;43(3 Suppl):S1-S17.
- Huang HC**, Weigt SS, Derhovanessian A, Paichevskiy V, Ardehali A, Saggari R, Saggari R, Kubak B, Gregson A, Ross DJ, Lynch JP 3rd, Elashoff R, Belperio JA. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant. 2011 Jul;30(7):790-8.
- Verleden GM**, Vos R, van Raemdonck D, Vanaudenaerde B. Pulmonary infection defense after lung transplantation: does airway ischemia play a role? Curr Opin Organ Transplant. 2010 Oct;15(5):568-71.
- Gilljam M**, Scherstén H, Silverborn M, Jönsson B, Ericsson Hollsing A. Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros. 2010 Jul;9(4):272-6.
- Liu M**, Mallory GB, Schechter MG, Worley S, Arrigan S, Robertson J, Elidemir O, Danziger-Isakov LA. Long-term impact of respiratory viral infection after pediatric lung transplantation. Pediatr Transplant. 2010 May;14(3):431-6. **Lefeuvre S**, Chevalier P, Charpentier C, Zekkour R, Havard L, Benammar M, Amrein C, Boussaud V, Lillo-Le Louët A, Guillemain R, Billaud EM. Valganciclovir prophylaxis for cytomegalovirus infection in thoracic transplant patients: retrospective study of efficacy, safety, and drug exposure. Transpl Infect Dis. 2010 Jun;12(3):213-9.
- Ranganathan K**, Worley S, Michaels MG, Arrigan S, Aurora P, Ballmann M, Boyer D, Conrad C, Eichler I, Elidemir O, Goldfarb S, Mallory GB Jr, Mogayzel PJ, Parakininkas D, Solomon M, Visner G, Sweet SC, Faro A, Danziger-Isakov L. Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation. J Heart Lung Transplant. 2009 Oct;28(10):1050-6.

IV. MALIGNANCIES FOLLOWING LUNG TRANSPLANTATION

Learning Objectives for Malignancies Following Lung Transplantation:

- 65) To review the high incidence of skin cancer and PTLD in lung transplant recipients.
- 66) To examine why lung transplant recipients are at increased risk for skin cancer and PTLD.
- 67) To discuss skin cancer surveillance and treatment approaches, including certain contraindications for lung transplant recipients.
- 68) To describe how to recognize, diagnose and treat pulmonary and extrapulmonary PTLD.
- 69) To recognize the complicated management of other malignancies that occur in lung transplant recipients, particularly lung cancer.
- 70) To recognize risk factors for malignancies and to develop screening strategies for at risk patients (especially GI malignancies in patients with Cystic Fibrosis and cervical / anal dysplasia in patients with HPV.)
- 71) To consider altered immunosuppression regimens as part of treatment plan for lung transplant patients with malignancies.

1. Incidence of malignancy in lung transplant recipients

- a. Increased rates of Skin Cancer and PTLD
- b. Other Malignancies

2. PTLD

- a. EBV
- b. Location – pulmonary vs. extrapulmonary

3. Skin Cancer

- a. Risk factors (? Role of voriconazole)
- b. Surveillance protocols
- c. Staging
- d. Management

4. Lung Cancer

- a. Incidental at time of transplant
- b. Transplant as therapy
- c. Management

5. Other malignancies

- a. Risk Factors (CF for GI malignancies, ILD / emphysema for lung cancer)
- b. Donor derived malignancies
- c. Locations

6. Cancer Screening in Lung Transplant Candidates

- a. Breast
- b. Lung
- c. Colon
- d. Prostate

7. Modulation of Immunosuppression

Selected References

- Yang RL**, Kurian AW, Winton LM, Weill D, Patel K, Kingham K, Wapnir IL. Addressing inherited predisposition for breast cancer in transplant recipients. *J Surg Oncol*. 2016 May;113(6):605-8.
- Ordóñez Dios IM**, Montoro Ballesteros F, Vaquero Barrios JM, Cobos Ceballos MJ, Redel Montero J, Santos Luna F. Analysis of the Incidence of Noncutaneous Neoplasia After Lung Transplantation and Its Impact on Prognosis. *Transplant Proc*. 2015 Nov;47(9):2659-60
- Redwan B**, Ziegeler S, Dickgreber N, Fischer S. Metastasectomy in a lung graft using high-flow venovenous extracorporeal lung support in a patient after single lung transplantation. *J Thorac Cardiovasc Surg*. 2015 Nov;150(5):e79-81.
- Nakajima T**, Cypel M, de Perrot M, Pierre A, Waddell T, Singer L, Roberts H, Keshavjee S, Yasufuku K. Retrospective Analysis of Lung Transplant Recipients Found to Have Unexpected Lung Cancer in Explanted Lungs. *Semin Thorac Cardiovasc Surg*. 2015 Spring;27(1):9-14. doi: 10.1053/j.semtcvs.2015.02.006. Epub 2015 Mar 7.
- Grewal AS**, Padera RF, Boukedes S, Divo M, Rosas IO, Camp PC, Fuhlbrigge A, Goldberg H, El-Chemaly S. Prevalence and outcome of lung cancer in lung transplant recipients. *Respir Med*. 2015 Mar;109(3):427-33.
- Kachala SS**, Murthy SC. Lung transplantation for multifocal lung adenocarcinoma (multifocal lung carcinoma). *Thorac Surg Clin*. 2014 Nov;24(4):485-91.
- Rashtak S**, Dierkhising RA, Kremers WK, Peters SG, Cassivi SD, Otley CC. Incidence and risk factors for skin cancer following lung transplantation. *J Am Acad Dermatol*. 2015 Jan;72(1):92-8.
- Olland AB**, Falcoz PE, Santelmo N, Kessler R, Massard G. Primary lung cancer in lung transplant recipients. *Ann Thorac Surg*. 2014 Jul;98(1):362-71.
- Rosengarten D**, Raviv Y, Rusanov V, Moreh-Rahav O, Fruchter O, Allen AM, Kramer MR. Radiation exposure and attributed cancer risk following lung transplantation. *Clin Transplant*. 2014 Mar;28(3):324-9.
- Mao W**, Xia W, Chen J. Lung transplantation for lung cancer. *Ann Thorac Surg*. 2013 Nov;96(5):1910.
- Hillen U**, Griewank K, Sommerwerck U, Baba HA, Schadendorf D. Tumor regression and sirolimus-based therapy in lung transplantation. *J Heart Lung Transplant*. 2013 Sep;32(9):938-9.
- Belli EV**, Landolfo K, Keller C, Thomas M, Odell J. Lung cancer following lung transplant: single institution 10 year experience. *Lung Cancer*. 2013 Sep;81(3):451-4.
- Muchtar E**, Kramer MR, Vidal L, Ram R, Gurion R, Rosenblat Y, Bakal I, Shpilberg O. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience. *Transplantation*. 2013 Oct 15;96(7):657-63.
- Strollo DC**, Dacic S, Ocak I, Pilewski J, Bermudez C, Crespo MM. Malignancies incidentally detected at lung transplantation: radiologic and pathologic features. *AJR Am J Roentgenol*. 2013 Jul;201(1):108-16.
- Na R**, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. De novo cancer-related death in Australian liver and cardiothoracic transplant recipients. *Am J Transplant*. 2013 May;13(5):1296-304.
- McLaughlin JM**, Equils O, Somerville KT, Aram JA, Schlamm HT, Welch VL, Mardekian J, Barbers RG. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients. *Transpl Infect Dis*. 2013 Aug;15(4):329-43. doi: 10.1111/tid.12063. Epub 2013 Mar 12. PubMed PMID: 23489832.
- Beaty CA**, George TJ, Kilic A, Conte JV, Shah AS. Pre-transplant malignancy: an analysis of outcomes after thoracic organ transplantation. *J Heart Lung Transplant*. 2013 Feb;32(2):202-11.
- Na R**, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. Comparison of de novo cancer incidence in Australian liver, heart and lung transplant recipients. *Am J Transplant*. 2013 Jan;13(1):174-83. **Sigurdardottir V**, Bjortuft O, Eiskjær H, Ekmehag B, Gude E, Gustafsson F, Hagerman I, Halme M, Lommi J, Mared L, Riise GC, Simonsen S. Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies. *J Heart Lung Transplant*. 2012 Dec;31(12):1276-80.
- Sampaio MS**, Cho YW, Qazi Y, Bunnapradist S, Hutchinson IV, Shah T. Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database. *Transplantation*. 2012 Nov 27;94(10):990-8.
- Espinosa D**, Baamonde C, Illana J, Arango E, Carrasco G, Moreno P, Algar FJ, Alvarez A, Cerezo F, Santos F, Vaquero JM, Redel J, Salvatierra A. Lung cancer in patients with lung transplants. *Transplant Proc*. 2012 Sep;44(7):2118-9.
- Machuca TN**, Keshavjee S. Transplantation for lung cancer. *Curr Opin Organ Transplant*. 2012 Oct;17(5):479-84.
- Ahmad U**, Wang Z, Bryant AS, Kim AW, Kukreja J, Mason DP, Bermudez CA, Detterbeck FC, Boffa DJ. Outcomes for lung transplantation for lung cancer in the United Network for Organ Sharing Registry. *Ann Thorac Surg*. 2012 Sep;94(3):935-40.
- Singer JP**, Boker A, Metchnikoff C, Binstock M, Boettger R, Golden JA, Glidden DV, Arron ST. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. *J Heart Lung Transplant*. 2012 Jul;31(7):694-9.
- de Boer M**, Vink A, van de Graaf EA. Non-small cell lung carcinoma of donor origin after bilateral lung transplantation. *Lung Cancer*. 2012 May;76(2):259-61.
- Metchnikoff C**, Mully T, Singer JP, Golden JA, Arron ST. The 7th edition AJCC staging system for cutaneous squamous cell carcinoma accurately predicts risk of recurrence for heart and lung transplant recipients. *J Am Acad Dermatol*. 2012 Nov;67(5):829-35.
- Ploenes T**, Passlick B. Lung cancer in the native lung after single-lung transplantation. *Asian Cardiovasc Thorac Ann*. 2011 Oct;19(5):372.
- von Boehmer L**, Draenert A, Jungraithmayr W, Inci I, Niklaus S, Boehler A, Hofer M, Stahel R, Soltermann A, van den Broek M, Weder W, Knuth A. Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. *Lung Cancer*. 2012 Apr;76(1):118-22.
- Parada MT**, Sepúlveda C, Alba A, Salas A. Malignancy development in lung transplant patients. *Transplant Proc*. 2011 Jul-Aug;43(6):2316-7.
- Verleden GM**, Fisher AJ. Lung transplantation and lung cancer: is there a link? *Respiration*. 2011;81(6):441-5.
- Buell JF**, Gross TG, Woodle ES. Malignancy after transplantation. *Transplantation*. 2005;80(2 Suppl):S254-264. 99.

V. MANAGEMENT OF METABOLIC COMPLICATIONS FOLLOWING LUNG TRANSPLANTATION

Learning Objectives for Management of Metabolic Complications Following Lung Transplantation:

- 72) To examine the metabolic consequences of prolonged immunosuppression therapy.
- 73) To discuss optimal management of diabetes mellitus following solid organ transplantation.
- 74) To review transplant specific issues regarding management of hypertension.
- 75) To determine an appropriate diagnostic and therapeutic management strategy for steroid induced osteoporosis / osteopenia.

1. Diabetes

- Role of post transplant immunosuppression medications
- Screening
- Therapy

2. Hypertension

- Role of post transplant immunosuppression medications
- Goals of therapy
- Therapy: medical therapies to use or avoid

3. Osteoporosis

- Diagnostic testing
- Therapeutic options- pharmacologic and non-pharmacologic therapies
- When to change or discontinue therapies

4. Metabolic Syndrome in Lung Transplant Recipients

Σ

Selected References

Diabetes:

Hayes D Jr, Patel AV, Black SM, McCoy KS, Kirkby S, Tobias JD, Mansour HM, Whitson BA. Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation. *J Thorac Cardiovasc Surg.* 2015 Sep;150(3):707-13.e2.

Hackman KL, Snell GI, Bach LA. Prevalence and predictors of diabetes after lung transplantation: a prospective, longitudinal study. *Diabetes Care.* 2014 Nov;37(11):2919-25.

Hackman KL, Bailey MJ, Snell GI, Bach LA. Diabetes is a major risk factor for mortality after lung transplantation. *Am J Transplant.* 2014 Feb;14(2):438-45.

Ye X, Kuo HT, Sampaio MS, Jiang Y, Bunnapradist S. Risk factors for development of new-onset diabetes mellitus after transplant in adult lung transplant recipients. *Clin Transplant.* 2011 Nov-Dec;25(6):885-91.

Bodziak KA, Hricik DE. New-onset diabetes mellitus after solid organ transplantation. *Transpl Int.* 2009 May;22(5):519-30.

Ollech JE, Kramer MR, Peled N, Ollech A, Amital A, Medalion B, Saute M, Shitrit D. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors. *Eur J Cardiothorac Surg.* 2008 May;33(5):844-8.

Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa JV, Uchida K, Valentine H, Villamil F, Vincenti F, Wissing M. Guidelines for the treatment and management of new-onset diabetes after transplantation. *Clin Transplant.* 2005 Jun;19(3):291-8.

Marchetti P. New-onset diabetes after transplantation. *J Heart Lung Transplant.* 2004 May;23(5 Suppl):S194-201.

Paolillo JA, Boyle GJ, Law YM, Miller SA, Lawrence K, Wagner K, Pigula FA, Griffith BP, Webber SA. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. *Transplantation.* 2001 Jan 27;71(2):252-6.

Wagner K, Webber SA, Kurland G, Boyle GJ, Miller SA, Cipriani L, Griffith BP, Fricker FJ. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. *J Heart Lung Transplant.* 1997 Mar;16(3):275-82.

Hypertension

Silverborn M, Jeppsson A, Mårtensson G, Nilsson F. New-onset cardiovascular risk factors in lung transplant recipients. *J Heart Lung Transplant*. 2005 Oct;24(10):1536-43.

Kunst H, Thompson D, Hodson M. Hypertension as a marker for later development of end-stage renal failure after lung and heart-lung transplantation: a cohort study. *J Heart Lung Transplant*. 2004 Oct;23(10):1182-8.

Midvedt K, Neumayer HH. Management strategies for posttransplant hypertension. *Transplantation*. 2000 Dec 15;70(11 Suppl):SS64-9.

Morrison RJ, Short HD, Noon GP, Frost AE. Hypertension after lung transplantation. *J Heart Lung Transplant*. 1993 Nov-Dec;12(6 Pt 1):928-31.

Osteoporosis

Braith RW, Conner JA, Fulton MN, Lisor CF, Casey DP, Howe KS, Baz MA. Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. *J Heart Lung Transplant*. 2007 Feb;26(2):132-7.

Mitchell MJ, Baz MA, Fulton MN, Lisor CF, Braith RW. Resistance training prevents vertebral osteoporosis in lung transplant recipients. *Transplantation*. 2003 Aug 15;76(3):557-62.

Aris RM, Lester GE, Renner JB, Winders A, Denene Blackwood A, Lark RK, Ontjes DA. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. *Am J Respir Crit Care Med*. 2000 Sep;162(3 Pt 1):941-6.

Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: a prospective study. *Chest*. 2000 Feb;117(2):476-81.

Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. *Chest*. 1996 May;109(5):1176-83.

VI. REPRODUCTIVE HEALTH AFTER LUNG TRANSPLANTATION

Learning Objectives for Reproductive Health After Lung Transplantation:

- 76) To describe the implications on fertility and pregnancy of lung transplantation.
- 77) To identify the risks to the transplant recipient, the organ and the fetus.
- 78) To determine the medical care considerations during pregnancy in a lung transplant recipient.
- 79) To acknowledge the current outcomes for pregnancies in lung and heart-lung transplant recipients.
- 80) To develop a strategy to increase awareness of family planning options for patients undergoing lung transplantation.
- 81) To be able to counsel lung transplant recipients on contraception with an understanding of potential contraindications.

1. Reproductive implications

- a. Fertility
- b. Egg Preservation

2. Contraception

- a. Options for Lung Transplant Recipients
- b. Important considerations / potential contraindications

3. Pregnancy

- a. Risks to Mother
- b. Risks to Fetus
- c. Obstetric management
- d. Pharmacologic implications for lung transplant recipients

Selected References

Vos R, Ruttens D, Verleden SE, Vandermeulen E, Bellon H, Vanaudenaerde BM, Verleden GM. Pregnancy after heart and lung transplantation. *Best Pract Res Clin Obstet Gynaecol*. 2014 Nov;28(8):1146-62.

Greene CL, Barr ML, Schenkel FA, Worrell SG, Starnes VA, McFadden PM. Outcomes after pregnancy in living lobar lung transplantation. *Transplantation*. 2014 Oct 15;98(7):692-4.

Thakrar MV, Morley K, Lordan JL, Meachery G, Fisher AJ, Parry G, Corris PA. Pregnancy after lung and heart-lung transplantation. *J Heart Lung Transplant*. 2014 Jun;33(6):593-8.

Deshpande NA, Coscia LA, Gomez-Lobo V, Moritz MJ, Armenti VT. Pregnancy after solid organ transplantation: a guide for obstetric management. *Rev Obstet Gynecol*. 2013;6(3-4):116-125

Shaner J, Coscia LA, Constantinescu S, McGrory CH, Doria C, Moritz MJ, Armenti VT, Cowan SW. Pregnancy after lung transplant. *Prog Transplant*. 2012 Jun;22(2):134-40.

Estensen M, Gude E, Ekmeahag B, Lommi J, Bjortuft O, Mortensen S, Nystrom UM, Simonsen S. Pregnancy in heart- and heart/lung recipients can be problematic. *Scand Cardiovasc J*. 2011 Dec;45(6):349-53.

Wu DW, Wilt J, Restaino S. Pregnancy after thoracic organ transplantation. *Semin Perinatol*. 2007 Dec;31(6):354-62. Review. PubMed PMID: 18063119.

Sibanda N, Briggs JD, Davison JM, Johnson RJ, Rudge CJ. Pregnancy after organ transplantation: a report from the UK Transplant pregnancy registry. *Transplantation*. 2007 May 27;83(10):1301-7.

Gyi KM, Hodson ME, Yacoub MY. Pregnancy in cystic fibrosis lung transplant recipients: case series and review. *J Cyst Fibros*. 2006 Aug;5(3):171-5. Epub 2006 Jun 21

Malouf MA, Hopkins PM, Singleton L, Chhajed PN, Plit ML, Glanville AR. Sexual health issues after lung transplantation: importance of cervical screening. *J Heart Lung Transplant*. 2004 Jul;23(7):894-7.

Baron O, Hubaut J, Galetta D, Treilhaud M, Horeau D, Despins P, Michaud J, Haloun A. Pregnancy and heart-lung transplantation. *J Heart Lung Transplant*. 2002 Aug;21(8):914-7.

Kruszka SJ, Gherman RB. Successful pregnancy outcome in a lung transplant recipient with tacrolimus immunosuppression. A case report. *J Reprod Med*. 2002 Jan;47(1):60-2.

Gertner G, Coscia L, McGrory C, Moritz M, Armenti V. Pregnancy in lung transplant recipients. *Prog Transplant*. 2000 Jun;10(2):109-12.

ADDENDUM

First Edition date: August 2010

Second Edition Date: July 2017

[Waiver statement]

[Copyrights]

[Thanks and Acknowledgements]

International Society for Heart and Lung Transplantation

14673 Midway Road, Suite 200

Addison, TX 75001

972-490-9495

972-490-9499 (fax)

communications@ishlt.org

<http://www.ishlt.org>